Virus-Derived Peptides for Clinical Applications

Mingying Yang[†,‡], **Kegan Sunderland**[‡,§], and **Chuanbin Mao**[*,§,‖]

[†]Institute of Applied Bioresource Research, College of Animal Science, Zhejiang University, Yuhangtang Road 866, Hangzhou 310058, China

[§]Department of Chemistry & Biochemistry, Stephenson Life Science Research Center, University of Oklahoma, 101 Stephenson Parkway, Norman, Oklahoma 73019, United States

[‖]School of Materials Science and Engineering, Zhejiang University, Hangzhou, Zhejiang 310027, China

Abstract

Novel affinity agents with high specificity are needed to make progress in disease diagnosis and therapy. Over the last several years, peptides have been considered to have fundamental benefits over other affinity agents, such as antibodies, due to their fast blood clearance, low immunogenicity, rapid tissue penetration, and reproducible chemical synthesis. These features make peptides ideal affinity agents for applications in disease diagnostics and therapeutics for a wide variety of afflictions. Virus-derived peptide techniques provide a rapid, robust, and high-throughput way to identify organism-targeting peptides with high affinity and selectivity. Here, we will review viral peptide display techniques, how these techniques have been utilized to select new organism-targeting peptides, and their numerous biomedical applications with an emphasis on targeted imaging, diagnosis, and therapeutic techniques. In the future, these virus-derived peptides may be used as common diagnosis and therapeutics tools in local clinics.

Graphical abstract

[*]**Corresponding Author:** cbmao@ou.edu.
[‡]**Author Contributions**
M.Y. and K.S. contributed equally to this manuscript.
ORCID
Chuanbin Mao: 0000-0002-8142-3659

1. INTRODUCTION

The proper diagnosis and treatment of illnesses is of vital importance worldwide. For example, cancer is a major cause of human death worldwide.[1] In the United States, ~25% of deaths are caused by cancer. There were a projected 1 660 290 new cancer cases and 580 350 deaths in 2013.[2] In China, according to the National Death Survey conducted by the Ministry of Health, cancer is currently the second leading cause of death due to increasing cancer mortality rates in the past few years.[3] However, cancer patients are just one of many disease groups that can benefit from swift diagnoses and targeted treatments. Pathogens are another major cause of death. More than 9 million pathogen-related illness diagnoses are due to foodborne pathogens in the United States alone.[4] Bacterial pathogens such as *Salmonella enterica* and *Listeria monocytogenes* alone account for $3.3 billion and $2.6 billion in medical costs a year in the United States, respectively, and this only scratches the surface. It is estimated that just 14 foodborne pathogens account for $14 billion a year in medical costs for the United States.[5] Among other pathogens, fungal infections such as those caused by *Candida albicans* and *Paracoccidioides brasiliensis* can also be devastating. It is estimated that the most common fungal diseases in humans affect ~1.7 billion (or roughly 25%) of the general worldwide population. Despite the current availability of antifungal drugs, invasive fungal infections often have mortality rates exceeding 50%.[5] Additionally, viral diseases such as *orthopoxviruses* (*cowpox* and *monkeypox*) infections or avian influenza A, and parasitic illnesses such as malaria or schistosomiasis are also devastating.[6–10] Hence, there is an overwhelming need for disease detection and therapeutics. These techniques must be both more effective than currently lacking techniques and cost-effective so that they may be used more widely around the world. This Review will describe cutting edge techniques for disease detection and therapeutics centered around the development of short organism-binding peptide sequences developed through virus-peptide display technology.

Over the past few decades, researchers have devoted a huge effort and investment toward developing affinity agents, including antibodies, proteins, peptides, and nucleic acids.[11–19]

The use of peptides now has an ever-expanding role with unexpected applications and has even been implicated in virus communication to name just one unique role.[20] For example, it has been shown that phages can communicate with each other to make a group decision in regards to their life cycle using a peptide.[20] It would be of great importance to discover whether or not more dangerous viruses react in a similar manner. Among these applications, peptides possess several advantages in biomedical applications.[21–28] First, peptides can be easily obtained by chemical synthesis with a high yield and low cost. Second, due to their small molecular weight, peptides can enter cells and penetrate tissue easily, can be cleared in the blood rapidly, are quickly metabolized, and have a low immunogenic nature. Another advantage is that peptides do not need to be produced in animals, which makes them more ethical as well as economical than antibody-development techniques.[26] These advantages make peptides very appealing for biomedical applications, such as molecular imaging, disease diagnosis, and therapy.

Organism-targeting peptides, which can selectively bind to a specific type of organism with high affinity, have been derived from several different origins. One way to discover organism-targeting peptides is to use peptides that are ligands for specific cell-surface receptors. A good example of this is RGD (Arg-Gly-Asp) and its derivatives.[27,29–35] RGD is also one of the first tumor-homing peptides that was discovered by randomly synthesizing portions of the amino acid sequence from fibronectin.[36,37] RGD shows a high selectivity and strong affinity to the integrins that are highly expressed on the surface of some kinds of cells such as cancer cells and is useful in a number of applications.[38–41] This method of identifying peptides is based on guessing and checking, which can be very cumbersome for larger peptide sequences. Therefore, more efficient methods have gained interest. Some of the most effective strategies for discovering novel targeting peptides are evolutionary screening virus-peptide display techniques.[42–48] For example, through biopanning with phage, the well-known RGD motif has been rediscovered by Arap et al. as a longer sequence, CDCRGDCFC.[49] This has become a famous sequence now called RGD-4C.[41,49,50] Here, we will review these techniques including how they have been utilized to discover new organism-targeting peptides, as well as their applications in diagnosis, detection, and therapy. To date, there has not been a clinically focused review of the use of these virus-derived peptides for diagnosing, detecting, or treating viral, bacterial, parasitic, yeast, and fungal infections as well as other diseases in humans (Figure 1). Despite the massive potential impact of such treatments worldwide, this topic is relatively new and upcoming and has thus not been covered yet. Table 1 gives a few examples of human clinical trials involving virus-derived peptides. Additionally, an overview of the available virus-derived peptides can be found in Tables 2 (pathogen targeting), 3 (human cell-targeting), and 4 (tissue-targeting).

2. VIRAL LIBRARIES

Virus-peptide libraries are a mixture of millions of virus particles where each virus displays a unique and random set of peptides. There are two major types of viral libraries, one based on nonlytic or lytic bacteriophages (phages) and another based on adeno-associated viruses (AAVs). Filamentous fd and M13 phages, which are nonlytic bacteria-specific viruses (and are very similar in structure and morphology to each other), are the most widely adopted

phages in phage-display techniques.[109–112] They have a rodlike shape that is ~800 nm in length and ~6 nm in width (Figure 1).[113] The circular, single-stranded DNA genome is surrounded by a protein sheath consisting of ~2700 copies of one major coat protein (pVIII) and 5 copies each of four minor coat proteins (pIII and pVI on one tip and pVII and pIX on the other tip).[114] These coat proteins are encoded by corresponding genes located in the DNA genome. Foreign DNA that encodes for foreign peptide expression can be inserted into the phage genome to display any desired peptides on the surface of the protein sheath. [43,115,116] In other words, a foreign peptide can be fused to minor and/or major coat proteins to site-specifically display at the end and/or along the side wall of phage particles by DNA engineering methods. Lytic phages such as T7 phages have also become widely used.[117–120] Since phage display was introduced by George P. Smith in 1985,[121] this technique has proved to be one of the most powerful approaches for selecting affinity ligands, including cell/tissue and pathogen-targeting peptides.[122] Nowadays, phage display has been further developed in combination with other techniques, such as microfluidics or better analysis software, to improve its selection efficiency.[74,123–125] The most widely used phages for phage display are shown in Figure 2.

Adeno-associated virus type 2 (AAV2) libraries are an exciting alternative to phage-display libraries.[127–131] AAV2 belongs to the family *Parvovirdae* and measures roughly 22 nm in diameter. This virus does infect humans (and other primates) but is not currently known to cause any diseases and only elicits a very mild immune response in humans as demonstrated by phase I clinical trials.[132] AAV2 is also a replication-defective virus (the coding genes for replication are defective, thus preventing further replication and the lytic pathway to cell lysis), making it ideal as a gene-therapy vector.[128,133–136] In fact, there are even AAV2 products that are approved (by European Union) for human use in commercial gene therapy, such as Glybera that can control the production of lipoproteinlipase (which is necessary for processing and clearing fat-carrying chylomicron after eating fat-containing foods).[137] Incredibly, adenovirus vectors have been used in 22% of all gene-therapy clinical trials to date.[138] Several sites are available within the AAV2 capsid that allow for the incorporation of targeting peptides. Such sites enable the use of AAV2 to make a viral library much like phage libraries. AAV2 peptide libraries are primarily used in gene-therapy applications and are typically better for gene-therapy applications than phage libraries. With phages, the peptides discovered may not be used in the same context (attached to phages), and using the free form of these peptides without the phages may cause them to behave differently in terms of binding conformations. With the AAV2, peptides will not behave differently in the actual gene-therapy application because they stay displayed on AAV2 in the same manner as was selected from the AAV2 library (Figure 2) rather than often being used as free peptides (which happens more frequently with phages). That is to say, isolated peptides are synthesized individually rather than grouped together in their conformation on the surface of a virus when it comes to most phage-derived gene-therapy peptides. Additionally, even if a gene-therapy vector is created from a phage, the vector may not internalize properly for gene transduction nearly as well as AAV2 because phages do not naturally infect human cells.[128] As AAV2 naturally infects human cells, these problems can be overcome naturally when applied to gene-therapy techniques if the whole virus is used, thus eliminating the issues of not having the targeting peptides in the same spatial context as the selection for targeting

was done. With AAV2 libraries, peptides can be selected for a particular gene-therapy target without changing the vector to be used in the actual gene therapy. In addition, recent work has shown that gene-delivery systems using AAV2 can be tuned to have varying efficiencies as desired. For example, Gomez et al. demonstrated a system that can control AAV2 gene-delivery efficiency using a setup that is dependent on an external light stimuli.[139] Modulating the ratio of red to far-red light allows for controlling the activation of a light-switchable protein, phytochrome B, as well as a light-dependent interaction partner (phytochrome interacting factor 6). Thus, light can be used to allow tunable control of the efficiency of AAV2 gene delivery from 35% to 600% (relative to unengineered AAV2). This control may be helpful for dosage-related applications. For these reasons, AAV2 libraries are becoming more popular in peptide-targeted gene-therapy applications. A representative example of AAV2 display is shown in Figure 3.

There are also hybrid AAV libraries created by shuffling the DNA of the capsid genes of several different AAVs. The commonly used library for this is generated through shuffling the capsid genes for AAV 1, 2, 4, 5, 6, 8, 9, rh8, rh10, rh39, and AAVrh43. This technique allows for a maximum theoretical diversity of 2×10^7 capsids for this library.[108] This type of library was designed for the purpose of generating designer vectors, which are capable of transducing a greater variety of cell types during in vivo selection.[108] Its greater diversity (compared to traditional AAV2 libraries, which typically have a diversity of 10^6 for their capsids[140]) is intended to also help with the inherent heterogeneity that exists between animals of the same species used during each cycle of selection in vivo.[108]

3. SELECTING ORGANISM-TARGETING PEPTIDES BY VIRUS-PEPTIDE DISPLAY

Organism-targeting peptides can be evolutionarily selected by allowing the aforementioned viral libraries to interact with the target organisms in vitro, ex vivo, or in vivo (Figures 4 and 5). By using such a virus-peptide display technique, virus-derived peptides targeting pathogen (Table 2), human cells (Table 3), and tissues (Table 4) can be discovered and widely applied in human disease diagnosis and therapy.

Cell/tissue-targeting peptides can be selected from a phage library containing up to 10^9 phage clones, with each clone displaying a unique and random peptide, through an evolutionary screening process called biopanning.[42,115,141,142] The general biopanning procedures for discovering cell/tissue-targeting peptides from a phage library are as follows. [71,143–145] First, an input phage library containing billions of phage clones with randomly displayed peptides is incubated with target cells or tissues. Some phages bind to and/or internalize into target cells/tissues while others do not during incubation. Second, a washing buffer is used to remove the weakly bound and unbound phages from the cell/tissue surface. Third, the cell/tissue-targeting phages are eluted from the target cells/tissues using an elution buffer (or cell-internalized targeting phages are isolated from the cells using a lysis buffer). Fourth, the eluted cell/tissue-targeting phages are biologically amplified by infecting *E. coli* bacteria that are cultured and used to enrich the selected phages. The process from step one to step four is designated as one round of selection. The enriched library is considered as an

output for the previous round. The enriched library is used as a new input for the next round of selection. After 3–5 rounds of selection, the foreign DNA insert-coding region in a phage genome is sequenced to determine the peptides that are expressed on the phages. This is possible because the displayed peptides are genetically encoded by the phage genome (Figure 4).

AAV2 libraries contain up to 10^8 different capsid variants for selection. The overall concept of biopanning is very similar to phage libraries. For AAV2 libraries, the application is typically for tissue-directed gene therapies. Therefore, this example will be for in vivo biopanning. First, an AAV2 library is injected into the animal model. The tissue of interest is then harvested after 48 h. Library insert fragments from the AAV2 library in the DNA are isolated and amplified using a polymerase chain reaction (PCR). The insert DNA is then cloned into plasmids and transfected into 293T cells to produce a secondary AAV2 library for the next round of selection. After 2–5 rounds of selection, dominant (most frequently present) peptides are characterized. An example of AAV2 library biopanning is shown in Figure 5.[105]

4. VIRAL-INFECTION DETECTION AND DIAGNOSIS

4.1. Avian Influenza A

Phage-display technology has contributed a great deal of techniques for the diagnosis and detection of viruses that have plagued human health on a global scale. For example, the influenza virus belonging to the family *Orthomyxoviridae* contains three genera: influenza A, B, and C. Avian influenza A is of particular interest as it is highly contagious among poultry, birds, and other animals including humans.[8,146] The influenza A viruses have been classified into several subtypes for which the rapid and precise diagnosis of these infections can be laborious and time-consuming, demands appropriate laboratory facilities, and is expensive.[9] Recently, phage-display technology has been used to create a rapid, sensitive, and low-cost detection system for the influenza strain H5N1.[62] Briefly, nanobodies (the targeting peptides specific to the H5N1 virus) were selected using variable fragments of the camelid single-domain antibodies (VHHs) phage-display library. The selected peptide sequences were AAGPLSWYAHEFLEYSGHEYNY, TEHRGFDDNDYVLPALGARAANY, and AAPPLPDCYSGSWSPFTDEYNY. An enzyme-linked immunosorbent assay (ELISA) detection system was then established. To do this, the nanobody was biotinylated and directionally captured by streptavidin-coated ELISA plates capable of specifically capturing the H5N1 virus. Another nanobody conjugated with horseradish peroxidase (HRP) was then used to create the color change associated with detection of H5N1. The full method is illustrated in Figure 6.[62] In addition to detecting H5N1, the same group has also developed a system capable of detecting the influenza strains H7N2 and H3N2 using similar methods.[7,62,63]

4.2. Orthopoxviruses

The availability of rapid and reliable detection methods for orthopoxviruses can be highly valuable. After the eradication of the human-specific variola virus (smallpox), only the zoonoses (examples include Ebola virus, salmonellosis, and influenza) are still around.

Some orthopoxviruses among the zoonoses, such as cowpox and monkeypox, have the ability to infect nonreservoir species and will transfer to humans.[6,146,147] Through phage display and biopanning with a Ph.D.-12 phage-display peptide library kit (M13 phage), a peptide was isolated that was capable of binding orthopoxviruses including vaccinia virus, cowpox virus, monekypox virus, and potentially additional orthopoxviruses. The peptide, TADKLLYGLFKS, was extensively tested for binding by ELISA, surface plasmon resonance, nanoscale liquid chromatographic tandem mass spectrometry, peptide-based immunofluorescence, Western Blot, and electron microscopy. In addition to binding the virus itself, the peptide could also be used to selectively identify cowpox-infected HEp-2 cells by fluorescence microscopy, as shown in Figure 7. These data make the discovered peptide very promising in detecting and diagnosing these dangerous pathogens.[64]

5. BACTERIAL INFECTION DIAGNOSIS AND THERAPEUTICS

5.1. Klebsiella pneumoniae

Treating multidrug-resistant bacterial infections has become a major challenge in modern medicine. Gram-negative infections, such as *Klebsiella pneumoniae*, are among the most problematic because of their multidrug-resistance issues.[148] Antimicrobial drugs for *Klebsiella pneumoniae* are greatly needed.[149–151] Multidrug-resistant *Klebsiella pneumoniae* infections have now spread worldwide and have left clinicians with few options for current or near-future therapeutic alternatives. To resolve this problem, recent work has turned to phage-display technology to identify potential protective antibody fragments against *Klebsiella pneumoniae*. Using a naïve human single chain fragment variable-phage library (M13 phage), binding sequences were determined and further investigated to identify their common target antigen to be MrkA.[65] MrkA is a major protein within the type III fimbriae complex.[65] After the third round of biopanning, the output sequences were batch-converted into a scFV-Fc format, which carried a human IgG1 Fc fragment. This fragment was suitable for the subsequent higher-throughput as well as functional screens that were completed. A detailed approach on how to convert scFvs from biopanning into scFV-Fc fusion proteins expressed in mammalian cell lines can be found in the literature.[152] These results were then used to create serotype-independent MrkA antibodies, which were shown to reduce biofilm formation of *Klebsiella pneumoniae* in vitro (by activating an immune response) and confer protection against *Klebsiella pneumoniae* in multiple murine pneumonia models. Immunization with purified MrkA proteins in mice was shown to reduce the bacterial burden of *Klebsiella pneumoniae*, leading to a potential target for therapeutics and vaccines.[65]

5.2. Listeria monocytogenes

Listeria monocytogenes is a Gram-positive rod-shaped bacterium. This bacterium is commonly present in ready-to-eat foods, which require no further cooking.[153,154] It can grow under harsh conditions at temperatures as low as 4 °C, as acidic as pH 4.4, and at salt concentrations ranging up to 10% NaCl.[66,155] Infection by *Listeria monocytogenes* is a leading cause of death among foodborne illnesses. The mortality rate for *Listeria monocytogenes* ranges from 20 to 30%.[66] Recently, two novel *Listeria monocytogenes* specific phage clones were developed and isolated from a phage-display antibody fragment

library (M13 phage) derived from the variable domain of heavy-chain antibodies of immunized alpaca. The resulting antibody fragments (with peptide sequences AARRGPGTSVLSDDYDY and ATTRTPRVRLPTESREYTY) created through phage-display technology were able to detect the three serotypes of *Listeria monocytogenes* (1/2a, 1/2b, and 4b) responsible for 95% of documented human infections. The method used to detect the pathogen was an ELISA. The detection limit was 1×10^4 colony-forming units per milliliter, providing a new diagnosis and detection tool for *Listeria monocytogenes*.[66] While this technique does not have as low of a detection limit as established PCR techniques, it is cost-effective.[66,156]

5.3. Salmonella

Salmonella comprises two species, *bongori* and *enterica*, and often infects humans through food consumption.[157] Of the two, >99% of human *Salmonella* infections are from the subspecies *enterica*. While a variety of techniques are available for detecting *Salmonella* such as antibody techniques and real-time PCR, cheaper, more reliable techniques are still needed.[158,159] Recently, phage-display biopanning (with M13 phages) was used to select peptides against gamma-irradiated whole *Salmonella* cells. After 4 rounds of panning and extensive testing, the sequence NRPDSAQFWLHH was found to be most effective.[67] This peptide was then chemically synthesized and coupled to MyOne tosylactivated Dynabeads. The ability of the peptide to capture whole *Salmonella* cells from nonenriched broth cultures was then quantified by magnetic separation + plate counts, as well as by magnetic separation + Greenlight. Of these methods, the magnetic separation + Greenlight technique allowed for detections as low as 10 *Salmonellae* per milliliter, which may be sufficient to eliminate the need for pre-enrichment techniques in screening for *Salmonella*, thus speeding up the detection process (by a minimum of 8 h when compared to prevailing enrichment techniques).[67,160] This Greenlight system was developed by Luxcel Biosciences Limited and involves an oxygen-sensitive fluorescent probe (Greenlight probe). The probe's signal increases when oxygen levels decrease (due to bacteria presence), and a certain threshold time is measured. This threshold time corresponds to the minimum time necessary to get the first measurable change in oxygen levels for the sample compared to a pre-established standard curve for a target bacterium. Thus, after capturing *Salmonella* on the peptide-coated Dynabeads, the *Salmonella* could be concentrated by a magnetic separation and the concentration of bacteria could be determined using the Greenlight system (fluorescence levels directly correlate with *Salmonella* concentration due to oxygen consumption by the *Salmonella*).[67]

5.4. Staphylococcus aureus

Staphylococcus aureus is an opportunistic pathogen implicated in life-threatening diseases such as osteomyelitis, toxic shock syndrome, and endocarditis.[161] This pathogen is one of the major causes of wound infections and also arises as a complication during transfusion medicine techniques.[162] Existing methods for rapid detection are mainly reliant on antibodies and bioprobes, which can be tedious and expensive while having unintended cross-reactions. Recently, a synthetic peptide was developed utilizing phage-display technology (M13 phage) for the detection of *Staphylococcus aureus* bacteria. The peptide, VPHNPGLISLQG, was evaluated for its potential binding using immunoblot assays,

ELISA, and a dot-blot. The diagnostic potential was also evaluated in human platelet samples spiked with *Staphyloccus aureus*. The peptide was able to detect roughly 100 organisms per milliliter of spiked human platelet samples (in an ELISA), making it a potential clinical diagnostic method for detecting *Staphyloccus aureus* infections.[68]

5.5. Leprosy

Leprosy is caused by a chronic granulomatous infection from the bacteria *Mycobacterium leprae*. The disease affects the skin and peripheral nervous system. Treatment for leprosy is difficult due to a slow growth rate and long incubation periods of 3–10 years as well as their ability to escape a host's defense mechanism.[69] Multiple strains and drug-resistance development have made the problem even worse. In addition, *Myobacterium leprae* does not grow well in culture media. This makes fully assessing its antigenic structure for producing a vaccine difficult. To circumvent these issues, specific anti-*Myobacterium leprae* antibodies were isolated from 34 patients suffering from lepromatous leprosy and subsequently used in biopanning with a Ph.D.-12 phage-display library to select peptide sequences that could mimic the bacteria. These peptides can then be used to generate a potential vaccine against leprosy. Their potential was then evaluated for their ability to induce an anti-Leprae humoral response in mice. Specifically, the peptide epitope, LEQCQES, may be capable of being implemented in an early diagnosis technique for leprosy. These peptides were also able to invoke an anti-Leprae immune response in Balb/c mice, demonstrating their potential application as a vaccine.[69]

5.6. Tuberculosis

In 2013, tuberculosis was estimated to infect roughly 9 million people and killed 1.5 million people.[163] The early diagnosis of tuberculosis is essential in limiting the infection within a person and providing early treatment. Traditional bacteria-culturing diagnosis takes 6–8 weeks. However, serological antibody detection techniques available in more developed countries can be done on a much faster time scale.[163] Moreover, current commercially available tuberculosis antibody based tests continue to produce inconsistent results in terms of sensitivity and specificity.[163] Therefore, alternative strategies are needed. Recently, phage-display technology was used to develop a short peptide, WHLPLSL, capable of serologically detecting *Myobacterium tuberculosis* to diagnose tuberculosis.[70] The peptide was examined for its detection ability (in an ELISA test) using the sera from 47 tuberculosis patients and 37 healthy individuals. This research group had also determined from previous work that an antigen epitope peptide of a protein called mycobacterium protein 64 and a protein called CFP10/ESAT-6 could serve as an alternative corresponding antigen for the serological detection of tuberculosis. Therefore, out of the selected individuals, 12 tuberculosis patients with negative screening results for these 2 proteins were used as screening target sample controls (these patients had tuberculosis, but the previous CFP10/ESAT-6 method failed to detect it). Additionally, 12 healthy patients with similarly negative screening results for these proteins were selected as reverse screening sample controls (patients that did not have tuberculosis and also were negative for CFP10/ESAT-6). These data could serve as a comparison to see if the new detection method with the peptide WHLPLSL was superior to the previously established method (which sometimes failed to detect tuberculosis) of detecting the proteins mycobacterium protein 64 and CFP10/

ESAT-6.[70,164] It was demonstrated that the peptide, WHLPLSL, was a sensitive detection probe for the diagnosis of tuberculosis. Additionally, 3 other peptides showed promise but were not as effective as WHLPLSL in an ELISA.[70] Effectiveness was measured in terms of specificity (ability to correctly identify those without tuberculosis, who are the negative controls) and sensitivity (ability to correctly identify those patients with tuberculosis, who are the positive controls). Therefore, the best treatment option would have both a high sensitivity and a high specificity. All 4 peptides had >90% specificity, but WHLPLSL had the best sensitivity at 54%. That is to say, all 4 peptides did not misdiagnose healthy patients 90% of the time and the peptide WHLPLSL correctly identified tuberculosis 50% of the time. WHLPLSL is comparable to other existing mimotopes and antigens for detecting tuberculosis. It could be possible to combine the results of this new peptide, WHLPLSL, with the previous method of detecting mycobacterium protein 64 and CFP10/ESAT-6 to create an even more reliable method of detection. This could be done by picking the most consistent result among each test. For example, if two of the tests were positive and one negative, we could say that the positive result is more likely to be correct. This would reduce the chance of error. The results are demonstrated in Figure 8.

5.7. Otitis Media

Otitis media is a disease characterized by inflammation and fluid accumulation in the middle ear. Additional symptoms include ear pain, irritability in infants, and fever.[165] Although sometimes caused by viruses, it is primarily caused by infection with the bacteria *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Moraxella catarrhalis*.[106] Traditional treatments involve non-localized treatments such as antibiotics, which have additional undesired side-effects. The reason for the lack of local treatments is that the tympanic membrane, which is very difficult to penetrate by nonsurgical means, must be bypassed in order to get to the middle ear. For this reason, an alternative means to transport across the tympanic membrane of patients suffering from otitis media has recently been developed.[106] The technique involves using a peptide, SADSTKTTHLTL, developed through in vivo biopanning with a Ph.D-12 phage-display peptide library. The biopanning was carried out using male Sprague–Dawley rats infected with otitis media causing *Haemphilus influenza*. The library of phages was injected 2 days after the rats were infected with *Haemphilus influenza* (confirmed by the presence of fluid in the middle ear cavity). The phages were then collected from the middle ear fluid and counted by a standard plaque assay before entering the next round of biopanning. Validation of internalization and transiting efficiency of the selected peptides was determined by incubating specific phages over the tympanic membranes in vivo for 1 h followed by washings and elutions. The transiting efficiency was calculated by comparing the number of phages recovered from the middle ear fluid to the number of phages on the tympanic membrane input side. Additional transports kinetics, saturation, and competitive binding assays were also carried out on the most effective peptide identified, SADSTKTTHLTL. Overall, this study demonstrated the capability of the peptide SADSTKTTHLTL to transport across the tympanic membrane to the middle ear in otitis media infection. The system has the potential to transport otitis media treating drugs (such as antibiotics) across an intact unperforated tympanic membrane for the localized treatment of otitis media.[106]

6. PARASITE INFECTION TREATMENT AND PREVENTION

6.1. Rhipicephalus (Boophilus) microplus

Parasite species can be the cause of major health consequences for humans. They can be difficult to combat in our food sources. Additionally, parasites often transfer from insects such as ticks and mosquitos to humans. For example, the cattle tick, *Rhipicephalus (Boophilus) microplus*, is an ectoparasite (a parasite that lives on the outside of its host) in tropical and subtropical countries. Synthetic acaricides (pesticides toxic to the arachnid subclass, Acari, which includes ticks) and chemotherapy are the current treatments, but certain resistant tick populations have developed. Recently, phage display was used to develop 15-mer peptides (such as RNLWPGDLRWVGWH and RLGPLHFLNAWGHDH) capable of preferentially binding to either the eggs or larvae of the parasite. By identifying these binding peptides, future treatment opportunities will now be able to selectively target this parasite. The result is a proof of concept for utilizing phage-display technology, which could be applied to a wide range of other parasitic species, to provide suitable targets for vaccination and chemotherapy strategies.[55]

6.2. Malaria

Malaria is a devastating parasite often transmitted through mosquitos to humans and other animals. *Plasmodium* is a causative agent of malaria necessary to complete the life cycle of malaria in mosquitos, making it a valuable target for malaria prevention. Using phage display, a 12-mer peptide (PCQRAIFQSICN) was developed that is capable of strongly inhibiting the *Plasmodium* invasion of the salivary gland and midgut epithelia in mosquitos, thus impeding the life cycle of malaria.[56] Inhibition was a result of the peptide and sporozoites (the spore-like infective stage in the life cycle of the malaria parasite) recognizing the same ligand necessary for invasion of the salivary gland.

6.3. Schistosomiasis

Schistosomiasis is a tropical parasitic disease. Schistosomiasis infects up to 200 million people worldwide.[57] Schistosomiasis is caused by the blood flukes *S. hemeetobium*, *Schistosoma mansoni*, and *S. japonicum*. The parasitic infection is known to cause anemia, impaired cognition, stunted growth, and decreased physical fitness.[10] The current leading treatment of Schistosomiasis is chemotherapy with praziquantel.[10] Due to the potential of drug resistance and rapid reinfection after treatment, better techniques are necessary for treating the disease. Recently, the peptide sequence YSGLQDSSLRLR was discovered using phage-display techniques (with M13 phage). The biopanning process was carried out with the tegument (outer body covering) of live *Schistosoma japonicum* schistosomula being the target. Furthermore, both the peptide alone and the peptide conjugated to Rhodamine B were shown to bind and exhibit a potent schistosomicidal effect in vitro. It appears that the peptide negatively effects growth, development, and fecundity of *S. japonicum* in vivo, but the mechanism of this action is not clear. The system could be further improved by conjugation with probes, drugs, or immunological mediators to provide better diagnostic imaging or longer circulation times of the peptides.[57]

6.4. Cutaneous Leishmaniasis

Cutaneous leishmaniasis is caused by parasitic intracellular protozoan pathogens of the genus *Leishmania*. These *Leishmania* parasites are responsible for 2 million new infections per year.[51] There are no vaccines and limited chemotherapy options for cutaneous leishmaniasis. The very limited drug treatments available are highly toxic, requiring hospitalization.[166] In addition, parasites develop drug resistance. With an increasing incidence of therapeutic failures and drug resistance, there is a dire need for new treatments. [166] Recently, peptides developed through phage-display technology using a hexapeptide library (M13 phage pIII protein fusion) were found to be binding peptides for metacyclic promastigotes originating from a highly infectious strain of *Leishmania major*. The developed peptides were assessed in vitro on human monocytes infected with the disease as well as in vivo using a mouse model. The characteristic development of cutaneous lesions was shown to be protected against at a rate of 81.94% by utilizing the peptide MAAKYN in parasite-infected BALB/c mice. The peptide was shown to bind a major surface protease, gp63 (necessary for infection), and inhibit the growth kinetics of *Leishmania major*. The treatment effects of the peptide are shown in Figure 9. Taken together, this peptide shows great therapeutic promise in the treatment of *Leishmania major*.[51]

7. YEAST/FUNGAL INFECTION DIAGNOSIS AND TREATMENT

7.1. Candida albicans

Peptides have now become a powerful tool for combating yeast/fungal infections.[167] *Candida albicans* is a diploid fungus capable of growing as both yeast and filamentous cells. [168] It is a human pathogen growing in the gastrointestinal and genitourinary tracts. Delayed treatments of *Candida albicans* lead to increased mortality rates.[59,169] Established detection techniques can take up to 3 weeks to complete and lack reliability, resulting in an unnecessary treatment with toxic antifungals.[58] Recently, phage-display technology (using M13 phages) was used to develop peptides with a high degree of specificity toward the different morphological forms of *Candida albicans*. For example, the peptide ELMAVPVPLPPA is one of the many peptides that could be used for detecting this pathogen in an ELISA test. Coupled with an ELISA format, the use of these peptides allows for the specific and rapid detection of *Candida albicans* so that patients can get the appropriate drug therapy faster.[58]

Additionally, building off of previous work (by Ghadjari et al.),[60] our group developed an ultrasensitive, rapid detection virus-based ELISA system for detecting antibody biomarkers that indicate an infection with *Candida albicans*.[59] The viruses double-displayed peptides with targeting specificity toward magnetic nanoparticles and the *Candida albicans* disease biomarker antibody, antisecreted aspartyl proteinase 2 IgG. The previous work by Ghadjari et al. involved the discovery of the described antibody detecting peptide, VKYTS, by using phage-display library.[60] The second, magnetic nanoparticle-targeting sequence, PTYSLVPRLATQPFK, was developed by biopanning with an f88-15mer library using fd phage.[59] Together, by double-displaying these peptides on fd phages, the antibody-targeting peptide will bind to the disease biomarker antibody and the magnetic nanoparticle peptide will bind to the nanoparticles. By applying a magnet, the biomarker detection in sera can be

greatly enriched by concentrating the biomarkers. This allows for an average detection time of just 6 h compared to the previous gold standard of about 1 week. The detection limit for the new technique (1.1 pg/mL) is nearly 2 orders of magnitude lower than previously established antigen-based techniques.[59]

7.2. Paracoccidioidomycosis

Paracoccidioidomycosis is a disease caused by the *Paracoccidioides brasiliensis* fungus endemic in Latin America.[170] Recently, a CX7C phage library was utilized to create peptides targeting *P. brasiliensis*. Amazingly, the peptide CGSYGFNAC (derived from biopanning) was capable of targeting and killing only the virulent fungi. Furthermore, mice infected with *P. brasiliensis* had a highly significant reduction in lung colony-forming units upon treatment with the peptide. This was a result of the peptide binding to the fungus and preventing implantation of the fungus in the lungs (the primary site of infection for this fungus) and also inhibiting deployment of the fungus. This demonstrated the great potential of using this peptide for the treatment of paracoccidioidomycosis.[61]

8. DISCOVERY AND APPLICATIONS OF HUMAN CELL/TISSUE TARGETING PEPTIDES

8.1. Virus-Derived Peptides for Drug/Gene Delivery to Human Cells/Tissues

The main barrier for targeted delivery is a poor permeability of the cellular plasma membrane to a drug or gene. Recently, the potential of cell-targeting peptides for targeted delivery is highlighted due to their strong binding affinity and high recognition specificity. [171] In addition, their chemical stability and ease of conjugation allow them to be chemically coupled to a lot of therapeutics, including small-molecule chemotherapeutics, liposomes, and proteins. It is also worth mentioning that peptides discovered from one system such as phage display can be incorporated genetically into other systems for applications such as genetic imaging.[172] Table 3 summarizes some important human cell-targeting peptides derived from virus libraries and their typical applications.

8.1.1. Virus-Derived Peptides for Treating Cancer by Drug and Gene Delivery—
Perhaps the most important aspect of cancer treatment is early detection.[88] Ovarian cancer presents particular diagnosis problems due to the absence of reliable biomarkers. Ovarian cancer is also the most common cause of mortality among gynecological malignancies.[85] To overcome this issue, Wang et al. have developed an HO-8910 ovarian cancer cell targeting peptide, NPMIRRQ, through biopanning.[85] The peptide, derived from an M13 phage Ph.D.-7 library, demonstrated its ability to selectively bind ovarian cancer cells and not cervical cancer by immunofluorescence and immunohistochemical assays. The discovery of this peptide may have great potential in the future for diagnosing ovarian cancer.

Additionally, Zhou et al. have developed another HO-8910 ovarian cancer cell targeting peptide.[88] The peptide, SWQIGGN, was selected from a Ph.D.-C7C phage library. The peptide demonstrated an ability to control ovarian cancer cell migration, viability, adhesion capacity, invasion, and tumor growth in vivo. This peptide is in the process of being evaluated for clinical efficacy.[88]

Zhou et al.[173] have also conjugated two lung cancer cell-targeting peptides, TP H1299.1 and TP H2009.1, which were isolated from a 20-mer peptide library,[174] to the anticancer drug Doxorubicin, which is widely used in clinics.[175] The peptide sequence for TP H1299.1 is VSQTMRQTAVPLLWFWTGSL. The sequence for TP H2009.1 is RGDLATLRQLAQEDGVVGVR. The tetrameric peptide–doxorubicin conjugates could specifically deliver the drug and inhibit cell growth in target cells but not in nontarget control cells. In addition, Du et al.[78] exploited the potential of cell-targeting peptides for drug delivery in vivo. They isolated the A54 peptide (AGKGTPSLETTP) by in vivo phage display for hepatocarcinoma and also conjugated it to Doxorubicin for in vivo targeted therapy. The results in the A54-doxorubicin group showed a reduction in tumor size and prolongation of long-term survival compared to the control group. This indicated the effectiveness of the cell-targeting peptide for in vivo drug delivery.

Photodynamic therapy is another form of cancer treatment using light and photoactive compounds (photosensitizers) to kill cells. These photosensitizers produce singlet oxygen to induce cell death under light irradiation. As with many cancer therapies, the difficulty associated with treatment is precision targeting. Recently, a system utilizing the attachment of a photosensitizer, pyropheophorbide-*a* (PPa) conjugated to an SKBR-3 breast cancer targeting peptide (displayed on the side wall of fd phage) was developed for use in photodynamic therapy.[176] The fd phage used overcomes the precision-targeting issue by displaying a cancer-targeting peptide on its side wall constituted by pVIII major coat protein. The photosensitizer is then also conjugated to the N-terminal end of the breast cancer targeting peptides to create a precision targeting delivery system. The novel phage-enabled photosensitizers were able to selectively target and kill SKBR3 tumor cells in vitro. This system clearly demonstrates the power of phage-display technology in cancer treatment.

Acute myeloid leukemia is another deadly disease for which <40% of patients under 60 years of age can be cured.[84,177] While chemotherapy remains an option, gene therapy may be a more elegant solution. However, lack of specificity of viral and nonviral gene-therapy vectors to the cancerous cells is a major problem. To circumvent this issue, one group used an AAV2 display library to develop a peptide, NQVGSWS, that specifically targets acute myeloid leukemia cells. As AAV2 itself is already very useful for gene therapy, they were able to use the same virus with the discovered peptide as a targeted gene-therapy disease treatment for acute myeloid leukemia. The resulting vectors were loaded with a suicide gene and shown to selectively kill Kasumi-1 acute myeloid leukemia cells while not killing the control cells (CD34+ primary hematopoietic progenitor and peripheral blood mononuclear cells). Therefore, this technique may be a very promising alternative to existing strategies.[84]

Esophageal cancer is another common form of cancer.[178] Esophageal cancer is particularly challenging to identify early due to its lack of early clinical symptoms. This cancer is typically only diagnosed at an advanced stage and requires surgery, radiotherapy, and chemotherapy. To improve upon diagnosis, two novel peptides, RALAHPRDHPDL and ATCSMLLSRNEA, were discovered through biopanning with a Ph.D.-12 phage-display peptide library.[73] The peptides were evaluated and were shown to be a possible tool for early detection by an ELISA, immunofluorescence assay, and immunohistochemistry assay.[73] In

this ELISA, Eca109 cells and normal esophageal cells were cultured on 96-well plates overnight. Selected phages could then be incubated in the wells for 1 h at 37 °C. After washing away unbound phages, an anti-M13 monoclonal antibody was used along with a goat antimouse secondary antibody conjugated to horseradish peroxidase (HRP) in the presence of its 3,3′,5,5′-tetramethylbenzidine (TMB) substrate to detect phages at an absorbance of 490 nm. In this way, the phages could be used as a selective tool for detecting the Eca109 cells preferentially over normal esophageal cells.

8.1.2. Virus-Derived Peptides for Gene Delivery/Manipulation of Stem Cells—
Human pluripotent stem (hPS) cells are valuable for tissue engineering applications. Their ability to self-renew and differentiate into any cell type makes them invaluable for tissue-engineering applications. However, hPS cells must meet stringent Food and Drug Administration (FDA) requirements in terms of efficacy and safety before they can be used. Inappropriate stem cell types capable of forming tumors can contaminate pluripotent stem cells, presenting a major challenge for therapies involving the transplant of cells into patients. For this reason, Bignone et al. developed peptides through phage display for the identification, isolation, and expansion of desired pluripotent stem cells from a mix of normal and diseased donor-derived hPS cell lines. The selected embryonic progenitor cell-binding peptides, EWLFEFPTPVDA and DWIATWPDAVRS, were shown to preferentially bind to embryonic progenitor cells compared to RGD and biotin peptide controls in an immunofluorescence assay.[92]

Neural stem/progenitor cells provide a continuous source of new neurons in a healthy adult brain. These cells are particularly useful for repairing brain damage or treating diseases such as idiopathic Parkinson's disease. However, their ability to compensate for lost cells in damaged regions can be remediated by stimulation, which directs survival or differentiation. Preclinical studies of a peptide, SNQLPQQ, developed using a Ph.D.-7 phage-display library and later expressed on AAV for gene delivery to neural stem/progenitor cells, have shown promise in this area. However, the peptide developed has only been tested in mice so there is a need for a similar strategy in humans.[179]

8.1.3. Virus-Derived Vasculature Peptides—There is a great deal of diversity among all the receptors in human blood vessels. In light of this diversity, Arap et al. have made great progress by undergoing the first in vivo peptide library screening of a human patient's vasculature system.[53] In this clinical trial, >47 160 motifs were surveyed and found to localize to specific organs nonrandomly using a CX7C random phage-display peptide library after 15 min of circulation in the patient's vasculature system. Among these, there were several candidates for motifs that bind to bone marrow, fat, skin, muscle, and prostate tissues, as can be found in Table 4. This highly influential study was an important step for virus-derived peptide targeting. With the new targeting motifs discovered, a great deal more is now known about targeting organs and tissues of the human vasculature system.

Strong, sustained gene expression in a specific tissue after a simple injection of a vector is a major challenge. The pulmonary vasculature is a highly relevant tissue target for gene therapy in need of a tissue-targeting gene-delivery technique. Recently, an X_7 AAV2 library was utilized for screening peptides that efficiently target and deliver genes to the pulmonary

vasculature after intravenous administration. The peptide, ESGHGYF, was selected in vivo using FVB/N mice. After 48 h, the organs of interest were removed and tissue DNA was extracted. Oligonucleotides contained in AAV library particles, which were found to be enriched in the tissue of interest, were then amplified by PCR and used to produce secondary libraries. These secondary libraries were then used for further rounds of selection. Analysis by a luciferase reporter gene expression assay in vivo demonstrated the tissue homing ability of the gene therapy.[105] It should be noted that so far this peptide has only reached the preclinical stage, but with more work, strategies such as this will soon develop into the clinical trials stage.

8.1.4. Central Nervous System Virus-Derived Peptides—Central nervous system treatments require a high level of specificity due to the potentially complicated side-effects of such treatments. A peptide, CDCRGDCFC, discovered through phage display is capable of homing to multiple tumor types including carcinoma, sarcoma, and melanoma.[34] More recently, phase I clinical trials using this virus-derived peptide were carried out to treat recurrent malignant gliomas in the brain.[41] The purpose of the study was to determine the highest possible dosage of the drug, DNX-2401 (using the targeting sequence CDCRGDCFC) for use in tumor treatment. Additionally, DNX-2401 has demonstrated great potential in treating recurrent glioblastoma. For example, one clinical trial on humans showed that a patient has now survived >30 months after treatment with an absence of progression and no signs of needing further treatment. An additional two patients are now still alive after 23 months, but the study is still ongoing.[180]

Incontinentia pigmenti is the result of a rare X-linked dominant genetic defect.[181] The disease is lethal in males. The disease primarily affects the ectodermal tissues such as the central nervous system, skin, teeth, and eyes. It also causes delayed development, paralysis, intellectual disability, muscle spasms, and seizures. Vectors utilizing AAV can greatly improve accessibility to the central nervous system for gene-therapy applications. However, there is a lack of specificity to brain endothelial cells for these vectors. Recently, AAV has been used to develop an efficient brain-homing peptide with a high degree of specificity for this target tissue and endothelial cells.[107] The peptide, NRGTEWD, was developed through biopanning utilizing an AAV library. The mutant AAV displaying the targeting peptide was shown to demonstrate efficient, target-specific, long-lasting transgene expression in endothelial cell tissues associated with the blood–brain barrier. The AAV was administered by an intravenous injection, making it clinically easy to administer. As a proof of concept, preclinical trials were carried out to treat mice suffering from the genetic disorder incontinentia pigmenti. Incontinentia pigmenti is considered rare.[182] It is an X-linked (caused by a mutation on the X chromosome) genodermatosis, which usually causes anomalies in the skin, appendages, and other organs.[182] The gene therapy was shown to ameliorate the severe cerebrovascular pathology associated with incontinentia pigmenti. Not only does this provide a valuable treatment for incontinentia pigmenti, it also provides a proof of concept for a broader range of treatments for neurovascular diseases.[183]

Alternative central nervous system peptides have also been discovered utilizing an AAV library. For example, the peptide VDFAVNTEGVYSEPRPIGTRYLTRNL has been discovered utilizing an AAV library constructed as a hybrid of AAV 1, 2, 3, 4, 5, 6, 8, 9, rh8,

rh10, rh39, and AAVrh43 by shuffling the DNA of their capsid genes.[108] The peptide was selected through in vivo biopanning on mice. The peptide (displayed on AAV) was then evaluated for targeted gene-therapy applications using both mice and cat models. The extent of the efficiency of the gene-therapy method was evaluated by the expression of green fluorescent protein in the target tissues. The systemic injection of this new gene-therapy vector was found to result in widespread gene transfection throughout the central nervous system with the transduction of multiple neuronal subpopulations. In addition, the new gene-therapy vector was also shown to have a high efficiency for gene therapy in muscle, brain, spinal cord, lung, and pancreas tissues.[108]

8.2. Virus-Derived Peptides for Biomedical Imaging of Human Cells

Biomedical molecular imaging is an essential tool for the development of disease diagnostics.[95] Recently, much progress has been made in targeted molecular imaging of diseases,[184–186] which requires a molecular probe with a high affinity and selectivity. According to the fundamental advantages of peptides as discussed in the Introduction, cell- and tissue-targeting peptides have been widely used as an attractive probe in molecular-imaging applications.

8.2.1. Virus-Derived Stem Cell Imaging Peptides—With all the applications of stem cell therapies, it is also necessary to be able to image stem cells. Recently, Bignone et al.[94] discovered three cell-targeting peptides: W10-R2-11, W10-R2-21, and W10-R3-18, for the human embryonic progenitor cell line W10. The most promising peptide sequence was DWLWSFAPNVDT, which was called W10-R3-18. The peptides were discovered through biopanning with a Ph.D.-12 phage library (M13 phage). Each cell-targeting peptide was modified with quantum dots (Qdot) to form a peptide–Qdot complex, which was used to label cells for both quantitative analysis and flow cytometry-based cell separations. The percentage of peptide–Qdot complex-labeled W10 cells data was in accordance with qualitative data observed by fluorescence microscopy. Another example of Qdot-conjugated cell-targeting peptides for targeted imaging is the APW peptide (full peptide sequence from biopanning was APWHLSSQYSRT) for primate embryonic stem cells.[90] Confocal laser microscopy results indicated specific targeting of embryonic stem cells through peptide-conjugated Qdot for the first time.

8.2.2. Virus-Derived Cancer Cell Imaging Peptides—Cancer cell imaging is of vital importance for better understanding cancer as well as for providing an early diagnosis. The easiest strategy for cell-targeting peptide-based molecular imaging is to directly synthesize a fluorophore-labeled peptide. Zhang et al.[76] developed a CP15 peptide (with a sequence of VHLGYAT), derived from a Ph.D.-7 phage library, for colon cancer cells. The FITC-labeled CP15 peptides were used to image target cells. The fluorescence microscopy data demonstrated CP15 peptide was the most effective peptide in targeting the colon cancer cell lines SW480 and HT29. Kelly et al. identified another colon carcinoma HT29 cell-targeting peptide called RPMrel (having the sequence CPIEDRPMC) from a Ph.D.-CX7C phage library.[187] The FITC-conjugated RPMrel peptide only bound to HT29 colon carcinoma cells and colon tumor tissues, not to normal colon and noncolon tissues. Moreover, the conjugate

of the RPMrel peptide and mitochondrial toxin showed a cancer-killing ability, demonstrating the usage of the RPMrel peptide in drug delivery.

Radiolabeling of cell-targeting peptides provides an efficient route for in vivo imaging using several techniques. These techniques include positron emission tomography (PET) as well as single-photon emission computed tomography (SPECT).[188] The OSP-1 peptide (ASGALSPSRLDT) is a 143B osteosarcoma tumor cell targeting peptide derived from a Ph.D.-12 phage library.[189] The OSP-1 peptide was first coupled to Cy5.5 fluorescent dye to determine the binding affinity of OSP-1 in vitro and then radiolabeled by ^{18}F for in vivo microPET imaging. Results showed OSP-1 peptide had a high affinity and specificity to osteosarcoma cells both in vitro and in vivo (~2.5% ID/g), suggesting its potential for osteosarcoma diagnosis and treatment.

8.3. Virus-Derived Peptides for Biomedical Imaging/Treatment of Human Tissues

Apart from the cell-targeting peptides selected from in vitro phage display, some researchers used in vivo phage display to select tissue-targeting peptides. In addition, some cell-targeting peptides can also bind to their corresponding tissues. Several researchers have already applied these peptides for molecular imaging.

8.3.1. Tumor Tissue Imaging/Treatment—Current treatments for colorectal cancer in a metastatic setting are unsatisfactory.[190] Current epidermal growth factor (EGF) receptor targeted therapies are an established treatment method, but 85–90% of patients do not respond to this therapy.[72] It is known that mutations in EGF receptor downstream effectors such as KRAS (an oncogene that when mutated can cause normal cells to become cancerous) can cause a constitutive activation of the signaling pathway. This constitutive activation can allow for bypassing of the therapeutic block of the EGF receptor. Direct targeting attempts at KRAS by farnesyl transferase inhibitors have thus far failed.[72] Therefore, a better direct targeting method is needed that could lead to a better treatment for colorectal cancer. Bartolini et al. have made use of ex vivo/in vitro phage-display screens (Ph.D.-7 phage-display peptide library kit) to potentially solve this issue and show that basal cell adhesion molecule (BCAM) and laminin subunit alpha 5 (LAMA5) are molecular targets within human tumor cells that, when inhibited, cause impaired adhesion of KRAS mutant colorectal cancer cells to endothelial cells.[72] The expression of BCAM and LAMA5 was evaluated in preclinical human hepatic metastasis models (in mice having an intrahepatic implant of human colorectal cancer cell lines) as well as in 71 human patients. Two BCAM-mimetic peptides (ASGLLSLTSTLY and SSSLTLKVTSALSRDG) discovered from biopanning were chosen to be further evaluated and demonstrated antimetastatic efficacy. The two BCAM-mimetic peptides demonstrated efficacy against the hepatic colonization of human KRAS mutant colorectal cancer cells by inhibiting interactions with BCAM and LAMA5. This inhibition resulted in the abrogated adhesion of colorectal cancer cells to endothelial cells. The results are demonstrated in Figure 10.

Lee et al. used a T7 CX7C phage library to identify novel bladder tumor cell-targeting peptides, CSNRDARRC.[98] The fluorescein-conjugated CSNRDARRC peptides could bind to frozen sections of human bladder tumor tissue as well. Moreover, it could also detect

bladder tumor cells in patients' urine, suggesting its application in therapeutics delivery and bladder cancer diagnosis. Additionally, Yang et al. discovered the bladder tumor targeting peptides, CSSPIGRHC.[18] The peptide, discovered through biopanning, effectively imaged tumors as demonstrated by fluorescein isothiocyanate conjugation to the peptide followed by tumor imaging.

A new peptide has been discovered for breast tumor targeting. The discovery was based on the knowledge that the target of known tumor targeting peptides, CGNKRTRGC, works by binding to the mitochondrial chapter one protein, p32. Through biopanning using a T7 phage library, a new breast tumor targeting peptide, CKRGARSTC, was discovered.[96] The peptide was then incorporated into a surface-functionalized fluorescent silver nanoparticle and evaluated by injecting it intravenously into mice bearing a p32-expressing breast tumor. Imaging of the tumor tissue confirmed that the peptide was able to selectively target breast tumors.[96] However, this is only in the preclinical stage of development, and hopefully future work will move it into a clinical setting.

Recently, work has been completed studying tumor angiogenesis, which involves the formation of a new blood supply for tumors. It is therefore important in terms of the clinical management of various angiogenesis-dependent solid tumors. In this study, Merrill et al. used an FHT peptide sequence developed through biopanning with a phage library, which selectively binds the bone marrow-derived tumor vasculature.[191] The potential of the FHT-peptide (having the sequence FHTPSQNSAFRL) was then studied for the in vivo PET imaging of aggressive tumor vasculatures. Peptide sequences from biopanning were synthesized and labeled with the PET radionuclide, ^{64}Cu. The labeled peptides were characterized side-by-side with small animal PET and CT imaging at 1, 4, and 24 h after injection in a Lewis lung carcinoma subcutaneous tumor model. The peptide demonstrated a high tumor-to-background ratio and exceptional in vivo kinetic properties such as high affinity and tumor uptake (up to $5.05 \pm 1.20\%$ ID/g 24 h postinjection). It is thus an excellent potential diagnostic tool for radioimaging aggressive tumor vasculatures.[191]

Lung cancer is another widespread disease in need of better treatments and imaging techniques. Lung cancer is the most frequent type of cancer in the developed world and accounts for the most deaths among all cancers.[192] Lee et al. used an M13 phage Ph.D.-C7C phage-display peptide library to discover the peptide LYANSPF.[101] This peptide was shown to intensely and specifically bind human adenocarcinoma lung cancer cell-derived xenograft tissue in vitro and in vivo. Furthermore, the ability of these peptides on phages to target the tumor tissue was evaluated in terms of their imaging capability by using Cy5.5 labeled phages in vivo. This demonstrated the potential of using these peptides in future clinical applications relating to adenocarcinoma lung cancer.

8.3.2. Brown Adipose Tissue—The balance between white adipose tissue (WAT) and brown adipose tissue (BAT) determines the metabolic state of the body. However, identification of BAT in the body is still challenging. Azhdarinia et al.[102] discovered a novel BAT homing peptide sequence, CPATAERPC, from a CX_7C phage peptide library. A fluorophore IRDye800 was conjugated with the peptide CPATAERPC as a probe to localize brown adipose tissue depots by whole-body near-infrared fluorescence imaging, indicating

an approach to monitor changes in BAT/WAT distribution. In addition, this peptide also has the ability to target the vasculature of brown adipose tissue-like depots of subcutaneous white adipose tissue. This peptide may be useful in further studying the metabolic state of the body in relation to the balance between WAT and BAT.

8.3.3. Ischemic Stroke Tissue—Strokes frequently cause deaths as well as disabilities around the world. Strokes are a result of the sudden interruption of blood flow to the brain. Therapeutic techniques addressing strokes are in need of homing peptides that can target ischemic stroke tissue, identifying and detecting the apoptosis of cells. Hong et al.[104] discovered an ischemic stroke tissue-homing peptide sequence (CLEVSRKNC) and used fluorescein-labeled and ^{131}I-labeled peptides to radioimage ischemic stroke tissue and detect apoptotic neuronal cells. The fluorescent and autoradiographic images respectively demonstrated the viability of this peptide for targeting ischemic stroke tissue. In addition, the CLEVSRKNC peptide appears to bind to neuronal cells that are in a relatively early stage of apoptosis within a penumbra region while not binding to cells at later stages of apoptosis in the penumbra region and ischemic core. This is of great importance because the earlier stages of apoptosis may be reversible while the later stages are not, making this peptide a valuable tool. These results demonstrated its potential for drug delivery and the molecular imaging of stroke tissue.

8.4. Virus-Derived Peptides for Tissue Regeneration

The versatility of virus-derived peptides for diverse applications also extends to discovering new tissue-regenerative peptides.[193,194] For example, Caprini and co-workers developed a short peptide, KLPGWSG, that binds to neural stem cells and enhances differentiation toward the neuronal phenotype. The peptide was developed through biopanning with an M13 phage Ph.D.-7 library. These effects were characterized via rheometry and circular dichroism, atomic force microscopy, and assessing differentiation of cells in nanostructured hydrogels. Additionally, virus-based techniques can be used to better isolate the most effective peptides among known tissue-regenerative peptides. For example, we displayed several osteoblast-inducing peptides on M13 phages to test the effects of each peptide.[194] The comparison involved the peptides RGD, RGD/PHSRN (double-displayed), ALKRQGRTLYGFGG (osteogenic growth peptide), and KIPKASSVPTELSAISTLYL (from bone morphogenic protein 2). By creating phage films out of these different genetically engineered M13 phages, these peptides were able to be compared side by side in a relatively easy and cheap manner. This was done by culturing stem cells on the different phage films. By comparing the results of quantitative real-time PCR as well as the immunofluorescence of marker genes and proteins, respectively, each peptide could be assessed. The results demonstrated that the peptides ALKRQGRTLYGFGG and KIPKASSVPTELSAISTLYL were the most effective at differentiating induced pluripotent stem cells into osteoblasts. While this technique is not the typical biopanning method, it demonstrates an alternative way to derive clinically relevant peptides from using viral techniques.

8.5. Other Virus-Derived Peptide Applications for Human Cell Targets

Even though most of the virus-derived cell- and tissue-targeting peptides have been applied in targeted imaging and therapy, they can also find applications in other biomedical fields.

8.5.1. Bioseparation—Bioseparation techniques are another important application for which virus display has been used. McGuire et al.[195] selected two novel B cell lymphoma line A20-targeting peptides, SAKTAVSQRVWLPSHRGGEP and KSREHVNNSACPSKRITAAL, which were conjugated to magnetic beads to capture and isolate lymphoma cells. The capture of lymphoma cells was carried out by flow cytometry, which could be enriched with the use of a magnet to attract the magnetic beads. The peptides were isolated using a 20-mer M13 phage peptide library. This application could overcome the limitations of current attempts at treatment (radiation therapy, medication, possibly but rarely stem-cell transplantation, and chemotherapy) for lymphoma, which do not differentiate between normal and malignant cells.[195]

8.5.2. Identification of Drug-Binding Peptides—The various viral display libraries can be used to discover binding peptides to biologically beneficial drugs.[196] Sometimes, the mechanisms by which these drugs interact with human cells are unknown and we would benefit by being able to determine some of their binding characteristics. For example, oxymatrine is a biologically active drug derived from traditional Chinese medicine. Oxymatrine has been reported to have antiangiogenic effects in vitro and in vivo.[197] It also has antihepatic fibrosis effects as demonstrated in rats and humans. Inhibition of angiogenesis has been established as a way of treating liver fibrosis.[198] In this respect, oxymatrine has promise, but its mechanisms and interaction require more studying. Using a T7 phage cDNA library, Sun et al. were able to identify the short oxymatrine-binding peptide, UQCRB.[197] The interaction of the UQCRB peptide with oxymatrine was studied and confirmed by surface plasmon resonance as well as isothermal titration calorimetry. The specific binding sites of the peptide sequence to oxymatrine could be determined. This is important because it may provide key evidence as to where the drug oxymatrine is binding in vivo. For example, the same peptide motifs on a protein in vivo are likely interacting with the drug. Thus, phage-display technology can be a key tool for advancing our understanding of drug interactions.

9. PERSPECTIVES AND CHALLENGES

Currently, even in developed countries, there is a large disconnect between published diagnostic and therapeutic techniques in the literature and those available to the average consumer at local clinics. Patients visiting clinics due to diseases such as bacterial infections often leave no better off than when they came because either their infection is not the specific type of bacteria the clinic can detect or their infection is due to another organism such as a virus. Certainly, some of this can be attributed to the lag time between completing clinical trials and getting government approval, but cost-effectiveness, speed of diagnosis, accuracy, and expertise required to perform tests are other major limitations creating this disconnect. The use of short peptides developed through virus display technology for diagnosis and therapeutic techniques seeks to resolve this disconnect. These techniques are

fast and reliable and require significantly less expertise to implement than some existing techniques such as PCR or antibody-based techniques. Diagnosis utilizing virus display technologies can produce same-day reliable results whereas many previous gold standards could take up to a week, which is devastating for diseases that could have otherwise been treated with a much higher success rate if identified earlier.

Diagnostic and therapeutic peptides discovered through virus display currently face the challenge of being a relatively new field under development. Because of this, it will take some time to complete more widespread clinical trials and obtain approval from governments around the world. Essential questions need to be explored in more detail. Questions remain unanswered such as what is the fate of these peptides or their respective viruses (if the whole virus is used) in the human body? Certainly, there are many studies in terms of the immunogenicity of some viruses such as bacteriophage phi X174[199] (often used as a control for probing the strength of a person's immune system). However, there are a lack of studies on the major peptide-deriving virus libraries discussed in this Review. Additionally, it is not enough to answer these questions for just the wild-type strains, which creates a further degree of difficulty. We must answer what effect genetically displaying new peptides on these viruses has in terms of their fate in vivo as well as their immunogenicity (the same goes for free peptides). While this Review has provided information on several clinically relevant peptides, it is clear that there are far more diseases that are in need of similar studies. For example, noroviruses, *Clostridium perfrigens, Campylobacter*, and *Toxoplasma* are all major pathogenic diseases reported by the Center for Disease Control in the United States that could benefit from clinically relevant peptides.[200] With these issues addressed, the use of virus display technology may become widely acceptable in the medical industry, and eventually clinics will have the ability to diagnose and treat a far greater spectrum of diseases.

Despite this disconnect among clinically available peptides, there has been some progress. Table 1 summarizes some of the current human clinical trials using virus-derived peptides. In addition, many preclinical virus-derived peptides (Tables 2–4) have the potential to move into clinical trials in the coming years. It should be noted that there is a lack of AAV2-derived peptides in human clinical trials at this time despite the nearly endless amount of AAV2 (nonpeptide-related) clinical trials completed or underway. That is to say, displaying peptides on AAV2 needs to move from the preclinical stage to the clinical stage. It will be an exciting field to follow as new clinical trials using targeting peptides on AAV2 are used to improve a system that already shows great promise.

10. CONCLUSIONS

Virus-derived peptides for clinical applications are an exciting and expanding frontier in medicine. They have numerous advantages when compared to more traditional techniques such as antibodies. Peptides, once identified by the powerful and facile virus display technique, are easily obtained with a high yield, low cost, and consistent reproducibility. Peptides can enter cells as well as penetrate tissues. Additionally, the available techniques for deriving peptides from viral libraries allow for the highly selective identification of targeting peptides. These peptides have found wide-reaching medical applications for

targeting pathogens, human cells, and human tissues. While the peptides are developed to allow targeted diagnosis, imaging, or drug delivery, the peptides themselves have often been found to be an active treatment, as has been demonstrated with several pathogen-targeting peptides. To move the field further, it will be necessary to answer the essential questions on the in vivo fate as well as immunogenicity associated with these virus-derived peptide techniques. However, with the advances made, it may one day become commonplace to visit a local clinic that utilizes virus display technology techniques to diagnose a variety of illnesses.

Acknowledgments

Biographies

Mingying Yang completed her Ph.D. at the Tokyo University of Agriculture and Technology in 2005. Mingying then completed postdoctoral work at the same university before accepting a faculty position at Zhejiang University in 2007. Mingying's research involves peptide and protein nanostructures as well as their application in regenerative medicine and nanomedicine.

Kegan Sunderland holds Bachelor's degrees in mathematics and biochemistry from Hamline University. He completed his Master's degree and became a Ph.D. candidate in 2015 at the University of Oklahoma. Kegan is also a recipient of the Provost Distinction in Teaching award at the University of Oklahoma. The focuses of Kegan's research are virus-enabled nanomedicine, tissue engineering, and bionanomaterials.

Chuanbin Mao completed his Ph.D. in 1997 at the Northeastern University of China. Chuanbin then completed postdoctoral studies at Tsinghua University and later accepted a faculty position there. Chuanbin then became a visiting scholar at the University of Tennessee in Knoxville. Later he carried out postdoctoral studies at the University of Texas and then took a faculty position at the University of Oklahoma in 2005. He is a recipient of NSF CAREER award. Chuanbin's research interests are biomaterials, phage nanobiotechnology, regenerative medicine, and nanomedicine.

References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global Cancer Statistics. Ca-Cancer J Clin. 2011; 61:69–90. [PubMed: 21296855]

2. Siegel R, Naishadham D, Jemal A. Cancer Statistics, 2013. Ca-Cancer J Clin. 2013; 63:11–30. [PubMed: 23335087]

3. Chen WQ, Zeng HM, Zheng RS, Zhang SW, He J. Cancer Incidence and Mortality in China, 2007. Chin J Cancer Res. 2012; 24:1–8. [PubMed: 23359628]

4. Painter JA, Hoekstra RM, Ayers T, Tauxe RV, Braden CR, Angulo FJ, Griffin PM. Attribution of Foodborne Illnesses, Hospitalizations, and Deaths to Food Commodities by Using Outbreak Data, United States, 1998–2008. Emerging Infect Dis. 2013; 19:407–415. [PubMed: 23622497]

5. Hoffmann S, Batz MB, Morris JG Jr. Annual Cost of Illness and Quality-Adjusted Life Year Losses in the United States Due to 14 Foodborne Pathogens. J Food Prot. 2012; 75:1292–1302. [PubMed: 22980013]

6. Nolen LD, Osadebe L, Katomba J, Likofata J, Mukadi D, Monroe B, Doty J, Hughes CM, Kabamba J, Malekani J, et al. Extended Human-to-Human Transmission During a Monkeypox Outbreak in the Democratic Republic of the Congo. Emerging Infect Dis. 2016; 22:1014–1021. [PubMed: 27191380]

7. Zhu M, Hu Y, Li G, Ou W, Mao P, Xin S, Wan Y. Combining Magnetic Nanoparticle with Biotinylated Nanobodies for Rapid and Sensitive Detection of Influenza H3N2. Nanoscale Res Lett. 2014; 9:528. [PubMed: 25328501]

8. Vemula SV, Zhao J, Liu J, Wang X, Biswas S, Hewlett I. Current Approaches for Diagnosis of Influenza Virus Infections in Humans. Viruses. 2016; 8:96–111. [PubMed: 27077877]

9. McMullen AR, Anderson NW, Burnham C-AD. Pathology Consultation on Influenza Diagnostics. Am J Clin Pathol. 2016; 145:440–448. [PubMed: 27124947]

10. Zoni AC, Catalá L, Ault SK. Schistosomiasis Prevalence and Intensity of Infection in Latin America and the Caribbean Countries, 1942–2014: A Systematic Review in the Context of a Regional Elimination Goal. PLoS Neglected Trop Dis. 2016; 10:e0004493.

11. Meredith RF, Bueschen AJ, Khazaeli MB, Plott WE, Grizzle WE, Wheeler RH, Schlom J, Russell CD, Liu T, LoBuglio AF. Treatment of Metastatic Prostate Carcinoma with Radiolabeled Antibody Cc49. J Nucl Med. 1994; 35:1017–1022. [PubMed: 8195861]

12. Eary JF, Schroff RW, Abrams PG, Fritzberg AR, Morgan AC, Kasina S, Reno JM, Srinivasan A, Woodhouse CS, Wilbur DS, et al. Successful Imaging of Malignant Melanoma with Technetium-99m-Labeled Monoclonal Antibodies. J Nucl Med. 1989; 30:25–32. [PubMed: 2642954]

13. Wynant GE, Murphy GP, Horoszewicz JS, Neal CE, Collier BD, Mitchell E, Purnell G, Tyson I, Heal A, Abdel-Nabi H, et al. Immunoscintigraphy of Prostatic Cancer: Preliminary Results with 111in-Labeled Monoclonal Antibody 7e11-C53 (Cyt-356). Prostate. 1991; 18:229–241. [PubMed: 2020619]

14. Goldenberg DM. Targeted Therapy of Cancer with Radio-labeled Antibodies. J Nucl Med. 2002; 43:693–713. [PubMed: 11994535]

15. Keefe AD, Pai S, Ellington A. Aptamers as Therapeutics. Nat Rev Drug Discovery. 2010; 9:537–550. [PubMed: 20592747]

16. Zhu G, Ye M, Donovan MJ, Song E, Zhao Z, Tan W. Nucleic Acid Aptamers: An Emerging Frontier in Cancer Therapy. Chem Commun. 2012; 48:10472–10480.

17. Zhang Y, Hong H, Cai W. Tumor-Targeted Drug Delivery with Aptamers. Curr Med Chem. 2011; 18:4185–4194. [PubMed: 21838687]

18. Yang X, Zhang F, Luo J, Pang J, Yan S, Luo F, Liu J, Wang W, Cui Y, Su X. A New Non-Muscle-Invasive Bladder Tumor-Homing Peptide Identified by Phage Display in Vivo. Oncol Rep. 2016; 36:79–89. [PubMed: 27221614]

19. Kim MJ, Yu JH, Oh MH, Nam YS, Lee DY. Development of Fluorescence-Conjugated Islet-Homing Peptide Using Biopanning for Targeted Optical Imaging of Pancreatic Islet. J Ind Eng Chem. 2017; 45:404–411.

20. Davidson AR. Virology: Phages Make a Group Decision. Nature. 2017; 541:466–467. [PubMed: 28099417]

21. Boerman OC, Oyen WJ, Corstens FH. Radio-Labeled Receptor-Binding Peptides: A New Class of Radiopharmaceuticals. Semin Nucl Med. 2000; 30:195–208. [PubMed: 10928383]

22. Bolhassani A. Potential Efficacy of Cell-Penetrating Peptides for Nucleic Acid and Drug Delivery in Cancer. Biochim Biophys Acta, Rev Cancer. 2011; 1816:232–246.

23. Behr TM, Gotthardt M, Barth A, Behe M. Imaging Tumors with Peptide-Based Radioligands. Q J Nucl Med. 2001; 45:189–200. [PubMed: 11476170]

24. Vives E, Schmidt J, Pelegrin A. Cell-Penetrating and Cell-Targeting Peptides in Drug Delivery. Biochim Biophys Acta, Rev Cancer. 2008; 1786:126–138.

25. Liu R, Li X, Xiao W, Lam KS. Tumor-Targeting Peptides from Combinatorial Libraries. Adv Drug Delivery Rev. 2017:110–111. 13–37.

26. Wang Y, Wang Q, Wu A-h, Hao Z-p, Liu X-j. Isolation of a Peptide from Ph.D.-C7c Phage Display Library for Detection of Cry1ab. Anal Biochem. 2017; doi: 10.1016/j.ab.2017.03.004

27. Braun GB, Sugahara KN, Yu OM, Kotamraju VR, Mölder T, Lowy AM, Ruoslahti E, Teesalu T. Urokinase-Controlled Tumor Penetrating Peptide. J Controlled Release. 2016; 232:188–195.

28. Ogata AF, Edgar JM, Majumdar S, Briggs JS, Patterson SV, Tan MX, Kudlacek ST, Schneider CA, Weiss GA, Penner RM. Virus-Enabled Biosensor for Human Serum Albumin. Anal Chem. 2017; 89:1373–1381. [PubMed: 27989106]

29. Hart SL, Knight AM, Harbottle RP, Mistry A, Hunger HD, Cutler DF, Williamson R, Coutelle C. Cell Binding and Internalization by Filamentous Phage Displaying a Cyclic Arg-Gly-Asp-Containing Peptide. J Biol Chem. 1994; 269:12468–12474. [PubMed: 8175653]

30. Beer AJ, Haubner R, Sarbia M, Goebel M, Luderschmidt S, Grosu AL, Schnell O, Niemeyer M, Kessler H, Wester H-J, et al. Positron Emission Tomography Using [18f]Galacto-Rgd Identifies the Level of Integrin Alpha(V)Beta3 Expression in Man. Clin Cancer Res. 2006; 12:3942–3949. [PubMed: 16818691]

31. Pasqualini R, Koivunen E, Ruoslahti E. Alphav Integrins as Receptors for Tumor Targeting by Circulating Ligands. Nat Biotechnol. 1997; 15:542–546. [PubMed: 9181576]

32. Heckmann D, Kessler H. Design and Chemical Synthesis of Integrin Ligands. Methods Enzymol. 2007; 426:463–503. [PubMed: 17697896]

33. Wang J, Yang M, Zhu Y, Wang L, Tomsia AP, Mao C. Phage Nanofibers Induce Vascularized Osteogenesis in 3D Printed Bone Scaffolds. Adv Mater. 2014; 26:4961–4966. [PubMed: 24711251]

34. Simón-Gracia L, Hunt H, Scodeller P, Gaitzsch J, Kotamraju VR, Sugahara KN, Tammik O, Ruoslahti E, Battaglia G, Teesalu T. Irgd Peptide Conjugation Potentiates Intraperitoneal Tumor Delivery of Paclitaxel with Polymersomes. Biomaterials. 2016; 104:247–257. [PubMed: 27472162]

35. King A, Ndifon C, Lui S, Widdows K, Kotamraju VR, Agemy L, Teesalu T, Glazier JD, Cellesi F, Tirelli N. Tumor-Homing Peptides as Tools for Targeted Delivery of Payloads to the Placenta. Sci Adv. 2016; 2:e1600349. [PubMed: 27386551]

36. Gehlsen KR, Argraves WS, Pierschbacher MD, Ruoslahti E. Inhibition of in Vitro Tumor Cell Invasion by Arg-Gly-Asp-Containing Synthetic Peptides. J Cell Biol. 1988; 106:925–930. [PubMed: 2450101]

37. Pierschbacher M, Hayman EG, Ruoslahti E. Synthetic Peptide with Cell Attachment Activity of Fibronectin. Proc Natl Acad Sci USA. 1983; 80:1224–1227. [PubMed: 6572380]

38. Garanger E, Boturyn D, Dumy P. Tumor Targeting with Rgd Peptide Ligands-Design of New Molecular Conjugates for Imaging and Therapy of Cancers. Anti-Cancer Agents Med Chem. 2007; 7:552–558.

39. Hynes RO. Integrins: Bidirectional, Allosteric Signaling Machines. Cell. 2002; 110:673–687. [PubMed: 12297042]

40. Choi DS, Jin H-E, Yoo SY, Lee S-W. Cyclic RGD Peptide Incorporation on Phage Major Coat Proteins for Improved Internalization by Hela Cells. Bioconjugate Chem. 2014; 25:216–223.

41. Kitagawa T, Kosuge H, Uchida M, Iida Y, Dalman RL, Douglas T, McConnell MV. Rgd Targeting of Human Ferritin Iron Oxide Nanoparticles Enhances in Vivo Mri of Vascular Inflammation and Angiogenesis in Experimental Carotid Disease and Abdominal Aortic Aneurysm. Magn Reson Imaging. 2017; 45:1144–1153.

42. Smothers JF, Henikoff S, Carter P. Phage Display: Affinity Selection from Biological Libraries. Science. 2002; 298:621–622. [PubMed: 12386335]

43. Kehoe JW, Kay BK. Filamentous Phage Display in the New Millennium. Chem Rev. 2005; 105:4056–4072. [PubMed: 16277371]

44. Dasa SSK, Seamen ME, French BA, Kelly KA. Targeted Delivery of Therapeutic Agents after Myocardial Infarction. Circulation. 2014; 130:A12105–A12105.

45. Batonick M, Holland EG, Busygina V, Alderman D, Kay BK, Weiner MP, Kiss MM. Platform for High-Throughput Antibody Selection Using Synthetically-Designed Antibody Libraries. New Biotechnol. 2016; 33:565–573.

46. Kay B. Phage-Display and Related Areas. Methods. 2012; 58:1. [PubMed: 23127388]

47. Yao VJ, D'Angelo S, Butler KS, Theron C, Smith TL, Marchiò S, Gelovani JG, Sidman RL, Dobroff AS, Brinker CJ, et al. Ligand-Targeted Theranostic Nanomedicines against Cancer. J Controlled Release. 2016; 240:267–286.

48. Mann AP, Scodeller P, Hussain S, Joo J, Kwon E, Braun GB, Mölder T, She Z-G, Kotamraju VR, Ranscht B, et al. A Peptide for Targeted, Systemic Delivery of Imaging and Therapeutic Compounds into Acute Brain Injuries. Nat Commun. 2016; 7:11980. [PubMed: 27351915]

49. Arap W, Pasqualini R, Ruoslahti E. Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model. Science. 1998; 279:377–380. [PubMed: 9430587]

50. Adhikari P, Wen AM, French RH, Parsegian VA, Steinmetz NF, Podgornik R, Ching W-Y. Electronic Structure, Dielectric Response, and Surface Charge Distribution of RGD (1FUV) Peptide. Sci Rep. 2015; 4:5605.

51. Rhaiem RB, Houimel M. Targeting Leishmania Major Parasite with Peptides Derived from a Combinatorial Phage Display Library. Acta Trop. 2016; 159:11–19. [PubMed: 26995695]

52. U.S. National Institutes of Health. ClinicalTrials.gov (accessed 2017)

53. Arap W, Kolonin MG, Trepel M, Lahdenranta J, Cardó-Vila M, Giordano RJ, Mintz PJ, Ardelt PU, Yao VJ, Vidal CI, et al. Steps toward Mapping the Human Vasculature by Phage Display. Nat Med. 2002; 8:121–127. [PubMed: 11821895]

54. Oliner J, Min H, Leal J, Yu D, Rao S, You E, Tang X, Kim H, Meyer S, Han SJ, et al. Suppression of Angiogenesis and Tumor Growth by Selective Inhibition of Angiopoietin-2. Cancer Cell. 2004; 6:507–516. [PubMed: 15542434]

55. Bishop-Hurley SL, Strachan KA, Sutherland IA. The Application of Phage-Displayed Peptide Libraries to Ligand Detection in Eggs and Larvae of Rhipicephalus (Boophilus) Microplus. Vet Parasitol. 2010; 173:173–177. [PubMed: 20609525]

56. Ghosh AK, Ribolla PEM, Jacobs-Lorena M. Targeting Plasmodium Ligands on Mosquito Salivary Glands and Midgut with a Phage Display Peptide Library. Proc Natl Acad Sci USA. 2001; 98:13278–13281. [PubMed: 11687659]

57. Liu Y, Brindley PJ, Zeng Q, Li Y, Zhou J, Chen Y, Yang S, Zhang Z, Liu B, Cai L, et al. Identification of Phage Display Peptides with Affinity for the Tegument of Schistosoma Japonicum Schistosomula. Mol Biochem Parasitol. 2011; 180:86–98. [PubMed: 21930161]

58. Anandakumar S, Boosi KN, Bugatha H, Padmanabhan B, Sadhale PP. Phage Displayed Short Peptides against Cells of Candida Albicans Demonstrate Presence of Species, Morphology and Region Specific Carbohydrate Epitopes. PLoS One. 2011; 6:e16868. [PubMed: 21364990]

59. Wang Y, Ju Z, Cao B, Gao X, Zhu Y, Qiu P, Xu H, Pan P, Bao H, Wang L, et al. Ultrasensitive Rapid Detection of Human Serum Antibody Biomarkers by Biomarker-Capturing Viral Nanofibers. ACS Nano. 2015; 9:4475–4483. [PubMed: 25855864]

60. Ghadjari A, Matthews RC, Burnie JP. Epitope Mapping *Candida albicans* Proteinase (SAP 2). FEMS Immunol Med Microbiol. 1997; 19:115–123. [PubMed: 9395056]

61. Kioshima ES, Aliperti F, Maricato JT, Mortara RA, Bagagli E, Mariano M, Lopes JD. A Synthetic Peptide Selectively Kills Only Virulent Paracoccidioides Brasiliensis Yeasts. Microbes Infect. 2011; 13:251–260. [PubMed: 21070862]

62. Zhu M, Gong X, Hu Y, Ou W, Wan Y. Streptavidin-Biotin-Based Directional Double Nanobody Sandwich Elisa for Clinical Rapid and Sensitive Detection of Influenza H5n1. J Transl Med. 2014; 12:352. [PubMed: 25526777]

63. Gong X, Zhu M, Li G, Lu X, Wan Y. Specific Determination of Influenza H7N2 Virus Based on Biotinylated Single-Domain Antibody from a Phage-Displayed Library. Anal Biochem. 2016; 500:66–72. [PubMed: 26450565]

64. Miller L, Michel J, Vogt G, Döllinger J, Stern D, Piesker J, Nitsche A. Identification and Characterization of a Phage Display-Derived Peptide for Orthopoxvirus Detection. Anal Bioanal Chem. 2014; 406:7611–7621. [PubMed: 25311190]

65. Wang Q, Chang C-s, Pennini M, Pelletier M, Rajan S, Zha J, Chen Y, Cvitkovic R, Sadowska A, Thompson JH, et al. Target Agnostic Identification of Functional Monoclonal Antibodies against *Klebsiella pneumoniae* Multimeric MrkA Fimbrial Subunit. J Infect Dis. 2016; 213:1800–1808. [PubMed: 26768253]

66. Tu Z, Chen Q, Li Y, Xiong Y, Xu Y, Hu N, Tao Y. Identification and Characterization of Species-Specific Nanobodies for the Detection of Listeria Monocytogenes in Milk. Anal Biochem. 2016; 493:1–7. [PubMed: 26456330]

67. Morton J, Karoonuthaisiri N, Stewart L, Oplatowska M, Elliott C, Grant I. Production and Evaluation of the Utility of Novel Phage Display-Derived Peptide Ligands to Salmonella Spp. For Magnetic Separation. J Appl Microbiol. 2013; 115:271–281. [PubMed: 23551658]

68. Rao SS, Mohan KVK, Gao Y, Atreya CD. Identification and Evaluation of a Novel Peptide Binding to the Cell Surface of Staphylococcus Aureus. Microbiol Res. 2013; 168:106–112. [PubMed: 23017232]

69. Ferdosian M, Khatami MR, Malekshahi ZV, Mohammadi A, Kashani HH, Shooshtari MB. Identification of Immunotopes against Mycobacterium Leprae as Immune Targets Using Phdtm-12mer Phage Display Peptide Library. Trop J Pharm Res. 2015; 14:1153–1159.

70. Yang H, Sha W, Song P, Liu Z, Qin L, Huang X, Lu J, Wang J, Duthie MS, Xiao H, et al. Screening and Identification of Immunoactive Peptide Mimotopes for the Enhanced Serodiagnosis of Tuberculosis. Appl Microbiol Biotechnol. 2016; 100:2279–2287. [PubMed: 26577672]

71. Abbineni G, Modali S, Safiejko-Mroczka B, Petrenko VA, Mao C. Evolutionary Selection of New Breast Cancer Cell-Targeting Peptides and Phages with the Cell-Targeting Peptides Fully Displayed on the Major Coat and Their Effects on Actin Dynamics During Cell Internalization. Mol Pharmaceutics. 2010; 7:1629–1642.

72. Bartolini A, Cardaci S, Lamba S, Oddo D, Marchiò C, Cassoni P, Amoreo CA, Corti G, Testori A, Bussolino F, et al. Bcam and Lama5Mediate the Recognition between Tumor Cells and the Endothelium in the Metastatic Spreading of Kras-Mutant Colorectal Cancer. Clin Cancer Res. 2016; 22:4923–4933. [PubMed: 27143691]

73. Zhang Z-F, Shan X, Wang Y-X, Wang W, Feng S-Y, Cui Y-B. Screening and Selection of Peptides Specific for Esophageal Cancer Cells from a Phage Display Peptide Library. J Cardiothorac Surg. 2014; 9:76. [PubMed: 24779651]

74. Wang J, Liu Y, Teesalu T, Sugahara KN, Kotamrajua VR, Adams JD, Ferguson BS, Gong Q, Oh SS, Csordas AT, et al. Selection of Phage-Displayed Peptides on Live Adherent Cells in Microfluidic Channels. Proc Natl Acad Sci USA. 2011; 108:6909–6914. [PubMed: 21486998]

75. Yeh C-Y, Hsiao J-K, Wang Y-P, Lan C-H, Wu H-C. Peptide-Conjugated Nanoparticles for Targeted Imaging and Therapy of Prostate Cancer. Biomaterials. 2016; 99:1–15. [PubMed: 27209258]

76. Zhang Y, Chen J, Zhang Y, Hu Z, Hu D, Pan Y, Ou S, Liu G, Yin X, Zhao J, et al. Panning and Identification of a Colon Tumor Binding Peptide from a Phage Display Peptide Library. J Biomol Screening. 2007; 12:429–435.

77. Wu C, Lo SL, Boulaire J, Hong ML, Beh HM, Leung DS, Wang S. A Peptide-Based Carrier for Intracellular Delivery of Proteins into Malignant Glial Cells in Vitro. J Controlled Release. 2008; 130:140–145.

78. Du B, Han H, Wang Z, Kuang L, Wang L, Yu L, Wu M, Zhou Z, Qian M. Targeted Drug Delivery to Hepatocarcinoma in Vivo by Phage-Displayed Specific Binding Peptide. Mol Cancer Res. 2010; 8:135–144. [PubMed: 20145035]

79. Robinson P, Stuber D, Deryckere F, Tedbury P, Lagrange M, Orfanoudakis G. Identification Using Phage Display of Peptides Promoting Targeting and Internalization into Hpv-Transformed Cell Lines. J Mol Recognit. 2005; 18:175–182. [PubMed: 15384175]

80. Rasmussen UB, Schreiber V, Schultz H, Mischler F, Schughart K. Tumor Cell-Targeting by Phage-Displayed Peptides. Cancer Gene Ther. 2002; 9:606–612. [PubMed: 12082461]

81. Rittner K, Schreiber V, Erbs P, Lusky M. Targeting of Adenovirus Vectors Carrying a Tumor Cell-Specific Peptide: In Vitro and in Vivo Studies. Cancer Gene Ther. 2007; 14:509–518. [PubMed: 17318198]

82. Askoxylakis V, Zitzmann S, Mier W, Graham K, Kramer S, von Wegner F, Fink RHA, Schwab M, Eisenhut M, Haberkorn U. Preclinical Evaluation of the Breast Cancer Cell-Binding Peptide, p160. Clin Cancer Res. 2005; 11:6705–6712. [PubMed: 16166451]

83. Askoxylakis V, Mier W, Zitzmann S, Ehemann V, Zhang J, Kramer S, Beck C, Schwab M, Eisenhut M, Haberkorn U. Characterization and Development of a Peptide (p160) with Affinity for Neuroblastoma Cells. J Nucl Med. 2006; 47:981–988. [PubMed: 16741308]

84. Michelfelder S, Lee M-K, deLima-Hahn E, Wilmes T, Kaul F, Müller O, Kleinschmidt JA, Trepel M. Vectors Selected from Adeno-Associated Viral Display Peptide Libraries for Leukemia Cell–Targeted Cytotoxic Gene Therapy. Exp Hematol. 2007; 35:1766–1776. [PubMed: 17920758]

85. Wang L, Hu Y, Li W, Wang F, Lu X, Han X, Lv J, Chen J. Identification of a Peptide Specifically Targeting Ovarian Cancer by the Screening of a Phage Display Peptide Library. Oncol Lett. 2016; 11:4022–4026. [PubMed: 27313733]

86. Kang J, Zhao G, Lin T, Tang S, Xu G, Hu S, Bi Q, Guo C, Sun L, Han S, et al. A Peptide Derived from Phage Display Library Exhibits Anti-Tumor Activity by Targeting GRP78 in Gastric Cancer Multidrug Resistance Cells. Cancer Lett. 2013; 339:247–259. [PubMed: 23792224]

87. Han J, Gao X, Duan W, Lin F, Nie G, Xue Q, Huang Y, Duan Y, Wang Q, Hou Y. The Further Characterization of the Peptide Specifically Binding to Gastric Cancer. Mol Cell Probes. 2016; 30:125–131. [PubMed: 26808386]

88. Zhou C, Kang J, Wang X, Wei W, Jiang W. Phage Display Screening Identifies a Novel Peptide to Suppress Ovarian Cancer Cells in Vitro and in Vivo in Mouse Models. BMC Cancer. 2015; 15:889. [PubMed: 26555399]

89. Gross AL, Gillespie JW, Petrenko VA. Promiscuous Tumor Targeting Phage Proteins. Protein Eng, Des Sel. 2016; 29:93–103. [PubMed: 26764410]

90. Lu S, Xu X, Zhao W, Wu W, Yuan H, Shen H, Zhou C, Li LS, Ma L. Targeting of Embryonic Stem Cells by Peptide-Conjugated Quantum Dots. PLoS One. 2010; 5:e12075. [PubMed: 20711469]

91. Shao Z, Zhang X, Pi Y, Wang X, Jia Z, Zhu J, Dai L, Chen W, Yin L, Chen H, et al. Polycaprolactone Electrospun Mesh Conjugated with an MSC Affinity Peptide for MSC Homing in Vivo. Biomaterials. 2012; 33:3375–3387. [PubMed: 22322196]

92. Bignone, PA., Krupa, RA., West, MD., Larocca, D. Selection of Phage Display Peptides Targeting Human Pluripotent Stem Cell-Derived Progenitor Cell Lines. In: Turksen, K., Nagy, A., editors. Induced Pluripotent Stem (iPS) Cells: Methods and Protocols. Vol. 1. Springer New York: New York; 2016. p. 269-283.

93. Caprini A, Silva D, Zanoni I, Cunha C, Volontè C, Vescovi A, Gelain F. A Novel Bioactive Peptide: Assessing Its Activity over Murine Neural Stem Cells and Its Potential for Neural Tissue Engineering. New Biotechnol. 2013; 30:552–562.

94. Bignone PA, Krupa RA, Sternberg H, Funk WD, Snyder EY, West MD, Larocca D. Identification of Human Embryonic Progenitor Cell Targeting Peptides Using Phage Display. PLoS One. 2013; 8:e58200. [PubMed: 23483995]

95. Akerman ME, Chan WC, Laakkonen P, Bhatia SN, Ruoslahti E. Nanocrystal Targeting in Vivo. Proc Natl Acad Sci USA. 2002; 99:12617–12621. [PubMed: 12235356]

96. Paasonen L, Sharma S, Braun GB, Kotamraju VR, Chung TD, She ZG, Sugahara KN, Yliperttula M, Wu B, Pellecchia M, et al. New p32/gC1qR Ligands for Targeted Tumor Drug Delivery. ChemBioChem. 2016; 17:570–575. [PubMed: 26895508]

97. Zhang W-J, Sui Y-X, Budha A, Zheng J-B, Sun X-J, Hou Y-C, Wang TD, Lu S-Y. Affinity Peptide Developed by Phage Display Selection for Targeting Gastric Cancer. World J Gastroenterol. 2012; 18:2053–2060. [PubMed: 22563192]

98. Lee SM, Lee EJ, Hong HY, Kwon MK, Kwon TH, Choi JY, Park RW, Kwon TG, Yoo ES, Yoon GS, et al. Targeting Bladder Tumor Cells in Vivo and in the Urine with a Peptide Identified by Phage Display. Mol Cancer Res. 2007; 5:11–19. [PubMed: 17259343]

99. Zhi M, Wu KC, Dong L, Hao ZM, Deng TZ, Hong L, Liang SH, Zhao PT, Qiao TD, Wang Y, et al. Characterization of a Specific Phage-Displayed Peptide Binding to Vasculature of Human Gastric Cancer. Cancer Biol Ther. 2004; 3:1232–1235. [PubMed: 15492500]

100. Lee KJ, Lee JH, Chung HK, Ju EJ, Song SY, Jeong S-Y, Choi EK. Application of Peptide Displaying Phage as a Novel Diagnostic Probe for Human Lung Adenocarcinoma. Amino Acids. 2016; 48:1079–1086. [PubMed: 26759016]

101. Lee KJ, Lee JH, Chung HK, Choi J, Park J, Park SS, Ju EJ, Park J, Shin SH, Park HJ, et al. Novel Peptides Functionally Targeting in Vivo Human Lung Cancer Discovered by in Vivo Peptide Displayed Phage Screening. Amino Acids. 2015; 47:281–289. [PubMed: 25366491]

102. Azhdarinia A, Daquinag AC, Tseng C, Ghosh SC, Ghosh P, Amaya-Manzanares F, Sevick-Muraca E, Kolonin MG. A Peptide Probe for Targeted Brown Adipose Tissue Imaging. Nat Commun. 2013; 4:2472. [PubMed: 24045463]

103. Essler M, Ruoslahti E. Molecular Specialization of Breast Vasculature: A Breast-Homing Phage-Displayed Peptide Binds to Aminopeptidase P in Breast Vasculature. Proc Natl Acad Sci USA. 2002; 99:2252–2257. [PubMed: 11854520]

104. Hong HY, Choi JS, Kim YJ, Lee HY, Kwak W, Yoo J, Lee JT, Kwon TH, Kim IS, Han HS, et al. Detection of Apoptosis in a Rat Model of Focal Cerebral Ischemia Using a Homing Peptide Selected from in Vivo Phage Display. J Controlled Release. 2008; 131:167–172.

105. Korbelin J, Sieber T, Michelfelder S, Lunding L, Spies E, Hunger A, Alawi M, Rapti K, Indenbirken D, Muller OJ, et al. Pulmonary Targeting of Adeno-Associated Viral Vectors by Next-Generation Sequencing-Guided Screening of Random Capsid Displayed Peptide Libraries. Mol Ther. 2016; 24:1050–1061. [PubMed: 27018516]

106. Kurabi A, Pak KK, Bernhardt M, Baird A, Ryan AF. Discovery of a Biological Mechanism of Active Transport through the Tympanic Membrane to the Middle Ear. Sci Rep. 2016; 6:22663. [PubMed: 26946957]

107. Körbelin J, Dogbevia G, Michelfelder S, Ridder DA, Hunger A, Wenzel J, Seismann H, Lampe M, Bannach J, Pasparakis M, et al. A Brain Microvasculature Endothelial Cell-Specific Viral Vector with the Potential to Treat Neurovascular and Neurological Diseases. EMBO Mol Med. 2016; 8:609–625. [PubMed: 27137490]

108. Choudhury SR, Fitzpatrick Z, Harris AF, Maitland SA, Ferreira JS, Zhang Y, Ma S, Sharma RB, Gray-Edwards HL, Johnson JA, et al. In Vivo Selection Yields Aav-B1 Capsid for Central Nervous System and Muscle Gene Therapy. Mol Ther. 2016; 24:1247–1257. [PubMed: 27117222]

109. Ngweniform P, Abbineni G, Cao BR, Mao CB. Self-Assembly of Drug-Loaded Liposomes on Genetically Engineered Target-Recognizing M13 Phage: A Novel Nanocarrier for Targeted Drug Delivery. Small. 2009; 5:1963–1969. [PubMed: 19415651]

110. Sergeeva A, Kolonin MG, Molldrem JJ, Pasqualini R, Arap W. Display Technologies: Application for the Discovery of Drug and Gene Delivery Agents. Adv Drug Delivery Rev. 2006; 58:1622–1654.

111. Sidhu, SS., Geyer, CR. Phage Display in Biotechnology and Drug Discovery. 2nd. Vol. 1. CRC Press; 2015. p. 1-568.

112. Chung W-J, Kwon K-Y, Song J, Lee S-W. Evolutionary Screening of Collagen-Like Peptides That Nucleate Hydroxyapatite Crystals. Langmuir. 2011; 27:7620–7628. [PubMed: 21291244]

113. Irving MB, Pan O, Scott JK. Random-Peptide Libraries and Antigen-Fragment Libraries for Epitope Mapping and the Development of Vaccines and Diagnostics. Curr Opin Chem Biol. 2001; 5:314–324. [PubMed: 11479124]

114. Yang SH, Chung W-J, McFarland S, Lee S-W. Assembly of Bacteriophage into Functional Materials. Chem Rec. 2013; 13:43–59. [PubMed: 23280916]

115. Smith GP, Petrenko VA. Phage Display. Chem Rev. 1997; 97:391–410. [PubMed: 11848876]

116. Barbas, CF., Burton, DR., Scott, JK., Silverman, GJ. Phage Display: A Laboratory Manual. Vol. 1. Cold Spring Harbor Laboratory Press; 2001.

117. Danner S, Belasco JG. T7 Phage Display: A Novel Genetic Selection System for Cloning Rna-Binding Proteins from Cdna Libraries. Proc Natl Acad Sci USA. 2001; 98:12954–12959. [PubMed: 11606722]

118. Willats WG. Phage Display: Practicalities and Prospects. Plant Mol Biol. 2002; 50:837–854. [PubMed: 12516857]

119. Piggott AM, Karuso P. Identifying the Cellular Targets of Natural Products Using T7 Phage Display. Nat Prod Rep. 2016; 33:626–636. [PubMed: 26964751]

120. Zhou X, Cao P, Zhu Y, Lu W, Gu N, Mao C. Phage-Mediated Counting by the Naked Eye of Mirna Molecules at Attomolar Concentrations in a Petri Dish. Nat Mater. 2015; 14:1058–1064. [PubMed: 26280226]

121. Smith GP. Filamentous Fusion Phage: Novel Expression Vectors that Display Cloned Antigens on the Virion Surface. Science. 1985; 228:1315–1317. [PubMed: 4001944]

122. Yin L, Luo Y, Liang B, Wang F, Du M, Petrenko VA, Qiu H-J, Liu A. Specific Ligands for Classical Swine Fever Virus Screened from Landscape Phage Display Library. Antiviral Res. 2014; 109:68–71. [PubMed: 24977927]

123. Liu Y, Adams JD, Turner K, Cochran FV, Gambhir SS, Soh HT. Controlling the Selection Stringency of Phage Display Using a Microfluidic Device. Lab Chip. 2009; 9:1033–1036. [PubMed: 19350081]

124. Cung K, Slater RL, Cui Y, Jones SE, Ahmad H, Naik RR, McAlpine MC. Rapid, Multiplexed Microfluidic Phage Display. Lab Chip. 2012; 12:562–565. [PubMed: 22182980]

125. Brinton LT, Bauknight DK, Dasa SSK, Kelly KA. Phastpep: Analysis Software for Discovery of Cell-Selective Peptides Via Phage Display and Next-Generation Sequencing. PLoS One. 2016; 11:e0155244. [PubMed: 27186887]

126. Caberoy NB, Zhou Y, Jiang X, Alvarado G, Li W. Efficient Identification of Tubby-Binding Proteins by an Improved System of T7 Phage Display. J Mol Recognit. 2010; 23:74–83. [PubMed: 19718693]

127. Castle, MJ., Turunen, HT., Vandenberghe, LH., Wolfe, JH. Controlling Aav Tropism in the Nervous System with Natural and Engineered Capsids. In: Manfredsson, PF., editor. Gene Therapy for Neurological Disorders: Methods and Protocols. Vol. 1382. Springer New York; New York; 2016. p. 133-149.

128. Muller OJ, Kaul F, Weitzman MD, Pasqualini R, Arap W, Kleinschmidt JA, Trepel M. Random Peptide Libraries Displayed on Adeno-Associated Virus to Select for Targeted Gene Therapy Vectors. Nat Biotechnol. 2003; 21:1040–1046. [PubMed: 12897791]

129. Kotterman MA, Schaffer DV. Engineering Adeno-Associated Viruses for Clinical Gene Therapy. Nat Rev Genet. 2014; 15:445–451. [PubMed: 24840552]

130. Daya S, Berns KI. Gene Therapy Using Adeno-Associated Virus Vectors. Clin Microbiol Rev. 2008; 21:583–593. [PubMed: 18854481]

131. Wang J, Faust SM, Rabinowitz JE. The Next Step in Gene Delivery: Molecular Engineering of Adeno-Associated Virus Serotypes. J Mol Cell Cardiol. 2011; 50:793–802. [PubMed: 21029739]

132. McPhee SWJ, Janson CG, Li C, Samulski RJ, Camp AS, Francis J, Shera D, Lioutermann L, Feely M, Freese A, et al. Immune Responses to Aav in a Phase I Study for Canavan Disease. J Gene Med. 2006; 8:577–588. [PubMed: 16532510]

133. Monahan P, Samulski R. Aav Vectors: is Clinical Success on the Horizon? Gene Ther. 2000; 7:24–30. [PubMed: 10680012]

134. Salganik M, Hirsch ML, Samulski RJ. Adeno-Associated Virus as a Mammalian DNA Vector. Microbiol Spectrum. 2015; 3:1–32.

135. Wong FF, Ho ML, Yamagami M, Lam MT, Grande-Allen KJ, Suh J. Effective Gene Delivery to Valvular Interstitial Cells Using Adeno-Associated Virus Serotypes 2 and 3. Tissue Eng, Part C. 2015; 21:808–815.

136. Guenther CM, Kuypers BE, Lam MT, Robinson TM, Zhao J, Suh J. Synthetic Virology: Engineering Viruses for Gene Delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2014; 6:548–558. [PubMed: 25195922]

137. Bryant LM, Christopher DM, Giles AR, Hinderer C, Rodriguez JL, Smith JB, Traxler EA, Tycko J, Wojno AP, Wilson JM. Lessons Learned from the Clinical Development and Market Authorization of Glybera. Hum Gene Ther: Clin Dev. 2013; 24:55–64. [PubMed: 23808604]

138. Dmitriev, IP., Kaliberov, SA. Adenoviral Vectors for Gene Therapy. Vol. 1. Elsevier; 2016. Targeted Adenoviral Vectors I: Transductional Targeting; p. 1-231.

139. Gomez EJ, Gerhardt K, Judd J, Tabor JJ, Suh J. Light-Activated Nuclear Translocation of Adeno-Associated Virus Nanoparticles Using Phytochrome B for Enhanced, Tunable, and Spatially Programmable Gene Delivery. ACS Nano. 2016; 10:225–237. [PubMed: 26618393]

140. Koerber JT, Maheshri N, Kaspar BK, Schaffer DV. Construction of Diverse Adeno-Associated Viral Libraries for Directed Evolution of Enhanced Gene Delivery Vehicles. Nat Protoc. 2006; 1:701–706. [PubMed: 17406299]

141. Cao B, Mao C. Identification of Microtubule-Binding Domains on Microtubule-Associated Proteins by Major Coat Phage Display Technique. Biomacromolecules. 2009; 10:555–564. [PubMed: 19186939]

142. Lee S-W, Mao C, Flynn CE, Belcher AM. Ordering of Quantum Dots Using Genetically Engineered Viruses. Science. 2002; 296:892–895. [PubMed: 11988570]

143. McGuire MJ, Li S, Brown KC. Biopanning of Phage Displayed Peptide Libraries for the Isolation of Cell-Specific Ligands. Methods Mol Biol. 2009; 504:291–321. [PubMed: 19159104]

144. Brigati JR, Samoylova TI, Jayanna PK, Petrenko VA. Phage Display for Generating Peptide Reagents. Curr Protoc Protein Sci. 2008; 51:1–27.

145. Dasa SSK, Xu Y, Seaman ME, French BA, Kelly KA. Development of Targeted Drug Delivery Agents for Cardiac Regeneration. Circulation. 2013; 128:A15171–A15171.

146. Fassbender P, Zange S, Ibrahim S, Zoeller G, Herbstreit F, Meyer H. Generalized Cowpox Virus Infection in a Patient with Hiv, Germany, 2012. Emerging Infect Dis. 2016; 22:553–555. [PubMed: 26891134]

147. Tamošiūnait A, Hoffmann D, Franke A, Schluckebier J, Tauscher K, Tischer BK, Beer M, Klopfleisch R, Osterrieder N. Histopathological and Immunohistochemical Studies of Cowpox Virus Replication in a Three-Dimensional Skin Model. J Comp Pathol. 2016; 155:55–61. [PubMed: 27291992]

148. Nordmann P, Cuzon G, Naas T. The Real Threat of Klebsiella Pneumoniae Carbapenemase-Producing Bacteria. Lancet Infect Dis. 2009; 9:228–236. [PubMed: 19324295]

149. Fazili T, Sharngoe C, Endy T, Kiska D, Javaid W, Polhemus M. Klebsiella Pneumoniae Liver Abscess: An Emerging Disease. Am J Med Sci. 2016; 351:297–304. [PubMed: 26992260]

150. Yeh K-M, Chiu S-K, Lin C-L, Huang L-Y, Tsai Y-K, Chang J-C, Lin J-C, Chang F-Y, Siu L-K. Surface Antigens Contribute Differently to the Pathophysiological Features in Serotype K1 and K2 Klebsiella Pneumoniae Strains Isolated from Liver Abscesses. Gut Pathog. 2016; 8:4. [PubMed: 26893615]

151. Herkel T, Uvizl R, Doubravska L, Adamus M, Gabrhelik T, Htoutou Sedlakova M, Kolar M, Hanulik V, Pudova V, Langova K, et al. Epidemiology of Hospital-Acquired Pneumonia: Results of a Central European Multicenter, Prospective, Observational Study Compared with Data from the European Region. Biomed Pap. 2016; 160:448–455.

152. Xiao X, Chen Y, Mugabe S, Gao C, Tkaczyk C, Mazor Y, Pavlik P, Wu H, Dall'Acqua W, Chowdhury PS. A Novel Dual Expression Platform for High Throughput Functional Screening of Phage Libraries in Product Like Format. PLoS One. 2015; 10:e0140691. [PubMed: 26468955]

153. Marquis, H., Drevets, DA., Bronze, MS., Kathariou, S., Golos, TG., Iruretagoyena, JI. Human Emerging and Re-Emerging Infections. Vol. 1. John Wiley & Sons, Inc; 2015. Pathogenesis of Listeria Monocytogenes in Humans; p. 749-772.

154. Maury MM, Tsai Y-H, Charlier C, Touchon M, Chenal-Francisque V, Leclercq A, Criscuolo A, Gaultier C, Roussel S, Brisabois A, et al. Uncovering Listeria Monocytogenes Hypervirulence by Harnessing Its Biodiversity. Nat Genet. 2016; 48:308–313. [PubMed: 26829754]

155. Duché O, Trémoulet F, Glaser P, Labadie J. Salt Stress Proteins Induced in Listeria Monocytogenes. Appl Environ Microbiol. 2002; 68:1491–1498. [PubMed: 11916660]

156. Garrido A, Chapela M-J, Román B, Fajardo P, Lago J, Vieites JM, Cabado AG. A New Multiplex Real-Time Pcr Developed Method for Salmonella Spp. And Listeria Monocytogenes Detection in Food and Environmental Samples. Food Control. 2013; 30:76–85.

157. Makendi C, Page AJ, Wren BW, Le Thi Phuong T, Clare S, Hale C, Goulding D, Klemm EJ, Pickard D, Okoro C, et al. A Phylogenetic and Phenotypic Analysis of Salmonella Enterica Serovar Weltevreden, an Emerging Agent of Diarrheal Disease in Tropical Regions. PLoS Neglected Trop Dis. 2016; 10:e0004446.

158. Lee K-M, Runyon M, Herrman TJ, Phillips R, Hsieh J. Review of Salmonella Detection and Identification Methods: Aspects of Rapid Emergency Response and Food Safety. Food Control. 2015; 47:264–276.

159. Bell RL, Jarvis KG, Ottesen AR, McFarland MA, Brown EW. Recent and Emerging Innovations in Salmonella Detection: A Food and Environmental Perspective. Microb Biotechnol. 2016; 9:279–292. [PubMed: 27041363]

160. Myint MS, Johnson YJ, Tablante NL, Heckert RA. The Effect of Pre-Enrichment Protocol on the Sensitivity and Specificity of Pcr for Detection of Naturally Contaminated Salmonella in Raw Poultry Compared to Conventional Culture. Food Microbiol. 2006; 23:599–604. [PubMed: 16943057]

161. Tande AJ, Palraj BR, Osmon DR, Berbari EF, Baddour LM, Lohse CM, Steckelberg JM, Wilson WR, Sohail MR. Clinical Presentation, Risk Factors, and Outcomes of Hematogenous Prosthetic Joint Infection in Patients with Staphylococcus Aureus Bacteremia. Am J Med. 2016; 129:e11–e20.

162. Thomer L, Schneewind O, Missiakas D. Pathogenesis of Staphylococcus Aureus Bloodstream Infections. Annu Rev Pathol: Mech Dis. 2016; 11:343–364.

163. Steinmetz NF, Cho CF, Ablack A, Lewis JD, Manchester M. Cowpea Mosaic Virus Nanoparticles Target Surface Vimentin on Cancer Cells. Nanomedicine. 2011; 6:351–364. [PubMed: 21385137]

164. Yang H, Chen H, Liu Z, Ma H, Qin L, Jin R, Zheng R, Feng Y, Cui Z, Wang J, et al. A Novel B-Cell Epitope Identified within Mycobacterium Tuberculosis CFP10/ESAT-6 Protein. PLoS One. 2013; 8:e52848. [PubMed: 23308124]

165. Hirano T, Kodama S, Kawano T, Suzuki M. Accumulation of Regulatory T Cells and Chronic Inflammation in the Middle Ear in a Mouse Model of Chronic Otitis Media with Effusion Induced by Combined Eustachian Tube Blockage and Nontypeable Haemophilus Influenzae Infection. Infect Immun. 2016; 84:356–364. [PubMed: 26553466]

166. Faraj C, Yukich J, Adlaoui EB, Wahabi R, Mnzava AP, Kaddaf M, El Idrissi AL, Ameur B, Kleinschmidt I. Effectiveness and Cost of Insecticide-Treated Bed Nets and Indoor Residual Spraying for the Control of Cutaneous Leishmaniasis: A Cluster-Randomized Control Trial in Morocco. Am J Trop Med Hyg. 2016; 94:679–685. [PubMed: 26811431]

167. Huai Y, Dong S, Zhu Y, Li X, Cao B, Gao X, Yang M, Wang L, Mao C. Genetically Engineered Virus Nanofibers as an Efficient Vaccine for Preventing Fungal Infection. Adv Healthcare Mater. 2016; 5:786–794.

168. Thomson DD, Berman J, Brand AC. High Frame-Rate Resolution of Cell Division During Candida Albicans Filamentation. Fungal Genet Biol. 2016; 88:54–58. [PubMed: 26854071]

169. Rajendran R, Sherry L, Nile CJ, Sherriff A, Johnson EM, Hanson MF, Williams C, Munro CA, Jones BJ, Ramage G. Biofilm Formation is a Risk Factor for Mortality in Patients with Candida Albicans Bloodstream Infection—Scotland, 2012–2013. Clin Microbiol Infect. 2016; 22:87–93. [PubMed: 26432192]

170. Carvalho FMC, Busser FD, Freitas VLT, Furucho CR, Sadahiro A, Kono ASG, Criado PR, Moretti ML, Sato PK, Shikanai-Yasuda MA. Polymorphisms on Ifng, Il12b and Il12rb1 Genes and Paracoccidioidomycosis in the Brazilian Population. Infect, Genet Evol. 2016; 43:245–251. [PubMed: 27223631]

171. Gandra N, Wang D-D, Zhu Y, Mao C. Virus-Mimetic Cytoplasm-Cleavable Magnetic/Silica Nanoclusters for Enhanced Gene Delivery to Mesenchymal Stem Cells. Angew Chem, Int Ed. 2013; 52:11278–11281.

172. Ferrara F, Staquicini DI, Driessen WHP, D'Angelo S, Dobroff AS, Barry M, Lomo LC, Staquicini FI, Cardó-Vila M, Soghomonyan S, et al. Targeted Molecular-Genetic Imaging and Ligand-Directed Therapy in Aggressive Variant Prostate Cancer. Proc Natl Acad Sci USA. 2016; 113:12786–12791.

173. Zhou X, Chang YC, Oyama T, McGuire MJ, Brown KC. Cell-Specific Delivery of a Chemotherapeutic to Lung Cancer Cells. J Am Chem Soc. 2004; 126:15656–15657. [PubMed: 15571383]

174. Oyama T, Sykes KF, Samli KN, Minna JD, Johnston SA, Brown KC. Isolation of Lung Tumor Specific Peptides from a Random Peptide Library: Generation of Diagnostic and Cell-Targeting Reagents. Cancer Lett. 2003; 202:219–230. [PubMed: 14643452]

175. Huang YF, Shangguan D, Liu H, Phillips JA, Zhang X, Chen Y, Tan W. Molecular Assembly of an Aptamer-Drug Conjugate for Targeted Drug Delivery to Tumor Cells. ChemBioChem. 2009; 10:862–868. [PubMed: 19253922]

176. Gandra N, Abbineni G, Qu X, Huai Y, Wang L, Mao C. Bacteriophage Bionanowire as a Carrier for Both Cancer-Targeting Peptides and Photosensitizers and Its Use in Selective Cancer Cell Killing by Photodynamic Therapy. Small. 2013; 9:215–221. [PubMed: 23047655]

177. Stone RM, O'Donnell MR, Sekeres MA. Acute Myeloid Leukemia. ASH Education Program Book. 2004; 2004:98–117.

178. Torre LA, Siegel RL, Ward EM, Jemal A. Global Cancer Incidence and Mortality Rates and Trends—an Update. Cancer Epidemiol Biomarkers Prev. 2016; 25:16–27. [PubMed: 26667886]

179. Reetz J, Hildebrandt S, Schmidt A, Meier C, Herchenröder O, Gläser A, Witt M, Pützer BM, Wree A. Novel Subventricular Zone Early Progenitor Cell-Specific Adenovirus for in Vivo Therapy of Central Nervous System Disorders Reinforces Brain Stem Cell Heterogeneity. Brain Struct Funct. 2016; 221:2049–2059. [PubMed: 25761931]

180. Tejada S, Valle RD, Gallego J, Alonso MM, Peterkin J. Actr-15. A Phase I Study of the Oncolytic Virus Dnx-2401 and a Short Course Temozolomide for Glioblastoma at First Recurrence. J Neurooncol. 2016; 18:vi4–vi4.

181. Tomotaki S, Shibasaki J, Yunoki Y, Kishigami M, Imagawa T, Aida N, Toyoshima K, Itani Y. Effectiveness of Corticosteroid Therapy for Acute Neurological Symptoms in Incontinentia Pigmenti. Pediatr Neurol. 2016; 56:55–58. [PubMed: 26777982]

182. Mini S, Trpinac D, Obradovi M. Incontinentia Pigmenti Diagnostic Criteria Update. Clin Genet. 2014; 85:536–542. [PubMed: 23802866]

183. Barretto RPJ, Ko TH, Jung JC, Wang TJ, Capps G, Waters AC, Ziv Y, Attardo A, Recht L, Schnitzer MJ. Time-Lapse Imaging of Disease Progression in Deep Brain Areas Using Fluorescence Microendoscopy. Nat Med. 2011; 17:223–228. [PubMed: 21240263]

184. Glinsky VV, Glinsky GV, Glinskii OV, Huxley VH, Turk JR, Mossine VV, Deutscher SL, Pienta KJ, Quinn TP. Intravascular Metastatic Cancer Cell Homotypic Aggregation at the Sites of Primary Attachment to the Endothelium. Cancer Res. 2003; 63:3805–3811. [PubMed: 12839977]

185. Pierce MC, Javier DJ, Richards-Kortum R. Optical Contrast Agents and Imaging Systems for Detection and Diagnosis of Cancer. Int J Cancer. 2008; 123:1979–1990. [PubMed: 18712733]

186. Edwards WB, Xu B, Akers W, Cheney PP, Liang K, Rogers BE, Anderson CJ, Achilefu S. Agonist-Antagonist Dilemma in Molecular Imaging: Evaluation of a Monomolecular Multimodal Imaging Agent for the Somatostatin Receptor. Bioconjugate Chem. 2008; 19:192–200.

187. Kelly KA, Jones DA. Isolation of a Colon Tumor Specific Binding Peptide Using Phage Display Selection. Neoplasia. 2003; 5:437–444. [PubMed: 14670181]

188. Soendergaard M, Newton-Northup JR, Palmier MO, Deutscher SL. Peptide Phage Display for Discovery of Novel Biomarkers for Imaging and Therapy of Cell Subpopulations in Ovarian Cancer. J Mol Biomarkers Diagn. 2011; 2:004.

189. Sun X, Niu G, Yan Y, Yang M, Chen K, Ma Y, Chan N, Shen B, Chen X. Phage Display-Derived Peptides for Osteosarcoma Imaging. Clin Cancer Res. 2010; 16:4268–4277. [PubMed: 20570932]

190. Siegel R, DeSantis C, Jemal A. Colorectal Cancer Statistics, 2014. Ca-Cancer J Clin. 2014; 64:104–117. [PubMed: 24639052]

191. Merrill JR, Krajewski K, Yuan H, Frank JE, Lalush DS, Patterson C, Veleva A. Synthesis and Comparative Evaluation of Novel 64 Cu-Labeled High Affinity Cell-Specific Peptides for Positron Emission Tomography Imaging of Tumor Vasculature. Biomaterials. 2016; 84:241–249. [PubMed: 26839954]

192. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer Incidence and Mortality Worldwide: Sources, Methods and Major Patterns in Globocan 2012. Int J Cancer. 2015; 136:E359–E386. [PubMed: 25220842]

193. Gelain F, Cigognini D, Caprini A, Silva D, Colleoni B, Donega M, Antonini S, Cohen B, Vescovi A. New Bioactive Motifs and Their Use in Functionalized Self-Assembling Peptides for Nsc Differentiation and Neural Tissue Engineering. Nanoscale. 2012; 4:2946–2957. [PubMed: 22476090]

194. Wang J, Wang L, Yang M, Zhu Y, Tomsia A, Mao C. Untangling the Effects of Peptide Sequences and Nanotopographies in a Biomimetic Niche for Directed Differentiation of Ipscs by Assemblies of Genetically Engineered Viral Nanofibers. Nano Lett. 2014; 14:6850–6856. [PubMed: 25456151]

195. McGuire MJ, Samli KN, Chang YC, Brown KC. Novel Ligands for Cancer Diagnosis: Selection of Peptide Ligands for Identification and Isolation of B-Cell Lymphomas. Exp Hematol. 2006; 34:443–452. [PubMed: 16569591]

196. Takakusagi K, Takakusagi Y, Suzuki T, Toizaki A, Suzuki A, Kawakatsu Y, Watanabe M, Saito Y, Fukuda R, Nakazaki A, et al. Multimodal Biopanning of T7 Phage-Displayed Peptides Reveals Angiomotin as a Potential Receptor of the Anti-Angiogenic Macrolide Roxithromycin. Eur J Med Chem. 2015; 90:809–821. [PubMed: 25528335]

197. Sun, Y-h, Zhang, X-y, Xie, W-q, Liu, G-j, He, X-x, Huang, Y-l, Zhang, G-x, Wang, J., Kuang, Z-y, Zhang, R. Identification of Uqcrb as an Oxymatrine Recognizing Protein Using a T7 Phage Display Screen. J Ethnopharmacol. 2016; 193:133–139. [PubMed: 27497639]

198. Jian, Y-c, Li, W., He, Y., Jiang, M., Liu, Y-b, Xiong, W-j. Effect of Oxymatrine on Hepatic Gene Expression Profile in Experimental Liver Fibrosis of Rats. Chin J Integr Med. 2012; 18:445–450. [PubMed: 22821657]

199. Rash A, Dionisopoulos Z, Gilbert L, Tsoukas C. Assessment of Vaccine Competency to Recall and Neo-Antigens in a Cohort of Long-Term Successfully Treated Hiv Patients. J Allergy Clin Immunol. 2015; 135:AB95.

200. Scallan E, Hoekstra RM, Angulo FJ, Tauxe RV, Widdowson M-A, Roy SL, Jones JL, Griffin PM. Foodborne Illness Acquired in the United States—Major Pathogens. Emerging Infect Dis. 2011; 17:7–15. [PubMed: 21192848]

Figure 1.
Overview of clinical applications of virus-derived peptides. (A) Targeted drug transport. Virus-derived peptides can be used in a wide range of targeted treatment strategies. The peptides can provide targeting capabilities and allow for transport across physical barriers such as the blood–brain barrier or tympanic membrane. (B) Vaccines. Deriving a peptide that can serve as a vaccine is a multistep process. Typically, this involves biopanning against antibodies isolated from a diseased patient. The selected peptides, which mimic the original pathogen, are then displayed on a human-safe virus. This safe virus will then generate an immune response that will apply to both the mimetic and original pathogen, thus serving as a vaccine. (C) Pathogen therapeutics. Peptides derived from viruses can have antipathogenic effects. For example, the peptide MAAKYN was shown to inhibit the growth of the pathogen *Leishmania major* in BALB/c mice.[51] (D) Targeted cancer therapies. Virus-derived

peptides have been widely implemented in cancer diagnosis and imaging, as well as the targeted delivery of drugs to treat cancer. (E) Targeted gene therapy. Targeting peptides for gene therapy are not only derived from viruses, but in the case of adenovirus biopanning, the same virus selected from the biopanning process is subsequently employed for the gene-therapy application. (F) Disease detection. Enzyme-linked immunosorbent assays (ELISA) are often used for disease detection. A patient potentially suffering from a disease such as tuberculosis can have his or her serum quickly tested for the presence of this disease. If the disease is present, peptides (displayed on a human-safe virus) selected for binding to the disease specific pathogen will bind to the pathogen in the serum sample. A two-antibody detection system (often also involving horseradish peroxidase and 3,3′,5,5′-tetramethylbenzidine) can then be used to determine if the human-safe virus has bound to the potential target. If the target binding occurs, light is emitted, which can be detected, and the patient is diagnosed to have the disease.

Figure 2.
Phage display on M13 and T7 phages. For M13 phage, the 5 copies of pIII are usually utilized in phage libraries for biopanning. After a desired targeting sequence is obtained, that sequence may be genetically engineered into another M13 phage to be displayed on the much more plentiful pVIII. Biopanning is frequently done with pIII rather than pVIII for M13 phages. For T7 phage, the capsid is composed of 415 copies of the coat protein 10A and/or 10B. Through phage display, ~5–15 copies of the genetically engineered peptide sequence will be displayed on the C-terminus of capsid 10B.[126]

Figure 3.
Topology of the AAV2 capsid. Blue indicates position of the seven additional random amino acid residues near the distal portions of the 3-fold spikes on the AAV2 capsid surface. The inset shows a cross section through a spike region at a higher resolution with Arg588 shown in red and the adjacent seven amino acids (derived from the library insertion) shown in blue. [128] Adapted with permission from ref[128]. Copyright 2003 Nature Publishing Group.

Figure 4.
In vivo phage biopanning concept. A phage library displaying roughly one billion different combinations of peptides is injected into an animal model. Phages can migrate to their target organs, tissues, receptors, disease cells, etc. for which their peptides have the highest affinity. The phages are then recovered from the animal model by harvesting the desired target, such as a specific organ. The phages are then amplified and go through additional rounds of selection. After 3–4 rounds of selection, phages are sequenced to identify the high-affinity peptides achieved.

Figure 5.
In vivo peptide-selection strategy using an AAV2 library. First, an AAV2 library is injected into the animal model. The tissue of interest is then harvested after 6 days. Library insert fragments from the AAV2 library in the DNA are isolated and amplified using a polymerase chain reaction. The insert DNA is then cloned into plasmids and transfected into 293T cells to produce a secondary AAV2 library for the next round of selection (typically 2–5 rounds). [105] Adapted with permission from ref[105]. Copyright 2016 Elsevier.

Figure 6.
Overview of the selection process for determining VHHs specific to H5N1. All VHH genes specific to H5N1 were selected out of an immunized dromedary. Horseradish peroxidase, along with the various nanobodies coupled to biotin, were used in the detection strategy. The biotinylated nanobodies could be directionally captured by streptavidin in the microtiter plates. Essentially, the biotinylated nanobody (attached to streptavidin) would capture the H5N1 virus, and then another nanobody conjugated to horseradish peroxidase would allow for the detection of the assembly by measuring the absorbance at 450 nm.[62] Reproduced with permission from ref[62]. Copyright 2014 Springer.

Figure 7.
Peptide TADKLLYGLFKS can be used in the fluorescence labeling of cowpox-infected HEp-2 cells. (a) Bright-field image of cells. (b) Green fluorescent image of cells on glass slides incubated with the peptide and streptavidin–fluorescein isothiocyanate. (c) Cells were also incubated with a polyclonal anti-D8 antibody coupled to DyLight 649 (shown in red) to assess colocalization. (d) The nuclei of cells were stained by DAPI (blue). (e) Overlay of b, c, and d showing all stains. (f) Noninfected stained HEp-2 cells (control) do not show fluorescence.[64] Reproduced with permission from ref[64]. Copyright 2014 Springer.

Figure 8.
Detection of tuberculosis from the sera of tuberculosis patients ($n = 130$), disease control (control group of nontuberculosis patients that had a respiratory infectious disease) ($n = 20$), and healthy individuals ($n = 134$). The mean optical density value for each triplicate sample was read 20 min after the addition of a substrate in an ELISA. The scatter plot represents the distribution of IgG levels with respect to the four potential binding peptides. Plates were coated with 4 μg of peptides per well.[70] Adapted with permission from ref[70]. Copyright 2016 Springer.

Figure 9.
Inhibitory effect of selected peptides in infected tissues. (A) Inoculation of BALB/c mice with several virus library derived *L. major* inhibitory peptide candidates. *L. major* Glc 94 metacyclic promastigotes (1.0×10^6) were preincubated with 100 μM of peptides P1 (*MSKPKQ*), P2 (*MAAKYN*), P3 (*MAHYSG*), or control peptide, or with phosphate-buffered saline (PBS). Next, 5 mice per group were inoculated with these preincubated mixtures. The sizes of lesions were monitored with a Vernier caliper. Lesion sizes were calculated by subtracting the size of the contralateral-uninfected footpad. Swellings were monitored over a 13-week observation period every week. The results shown are the mean lesion size of 5 mice per group in millimeters. (B) Parasite burden in infected footpads. The burden was determined after draining the lymph nodes and spleens of mice by a limiting-dilution assay at week 13 postinfection. Results shown are the means ± the standard deviations of $\log_{10}$ dilutions at the three anatomical sites. These results include triplicates for each group with 5 individuals in a group.[51] Adapted with permission from ref[51]. Copyright 2016 Elsevier.

Figure 10.
Basal cell adhesion molecule (BCAM)-mimetic synthetic virus-derived peptides inhibition effect on the intrahepatic growth of human KRAS mutant colorectal cancer cells. The human colorectal cancer cell lines used were wild-type (WT) or mutant (HCT-116m, DLD-1) KRAS. The human cells were injected into immunosuppressed mice livers (5×10^6 cells/mouse) for 6–12 mice per group. The conditions indicated above were in the presence of a control peptide (scrambled peptide), ASGLLSLTSTLY (pep-BCAM1), or SSSLTLKVTSALSRDG (pepBCAM2). All peptides were administered at 100 μmol/L. Animals were sacrificed at 28 days after the implantation of human cells and peptides. Their livers were then explanted and photographed, and the external tumor areas were quantified. Differences between experimental groups were evaluated (depending on the number of mice/group) with a Fisher exact test or *t* test. Formalin-fixed, paraffin-embedded tissue

sections were subjected to a Mallory trichrome stain or immunostained (anti-Ki67, anti-LAMA5, or anti-BCAM antibodies). Tissues were then counterstained with hematoxylin. Pictures shown are from one representative mouse per group. BCAM and LAMA5, human proteins; BCAM and LAMA5 mouse proteins. **, $P < 0.01$; *, $P < 0.05$.[72] Reproduced with permission from ref[72]. Copyright 2016 American Association for Cancer Research.

Table 1

Examples of Virus-Derived Peptides in Clinical Trials for Humans

status/year	study title	brief description	condition	virus type used to discover peptides	reference
recruiting participants as of November, 2016	Electro-Phage and Colorimetric Aptamer Sensors for Clinical Staging and Monitoring of Bladder Cancer	seeks to identify a molecular fingerprint (peptide) capable of detecting recurrent bladder cancer using phage-display technology	bladder cancer	phage-display library to be used	52
not yet recruiting as of July, 2016	Peptide-Drug-Conjugates for Personalized, Targeted Therapy of Chronic Lymphocytic Leukemia	will use phage libraries to isolate phages specifically internalized by chronic lymphocytic leukemia cells taken from newly diagnosed and untreated patients; following treatment options will then be tailored to the specific patient's results in terms of binding peptides isolated from each patient's individualized biopanning study	chronic lymphocytic leukemia	phage-display library to be used	52
study is ongoing as of April, 2014	Gluten-free Diet in Gluten-Genetically Predisposed Subjects	will measure gluten-dependent humoral immune response by means of phage-display libraries before and after 12 months of a gluten-free diet; seeks to demonstrate the mucosal gluten-dependent response in relation to a gluten-free diet; will also evaluate the targeting specificity of a double staining technique for detecting IgA antitransglutaminase mucosal deposits utilizing antibody fragments developed through phage display	celiac disease	phage-display library to be used	52
study completed, 2002	Steps toward Mapping the Human Vasculature by Phage Display	carried out on a 48-year-old male Caucasian patient with the intention of mapping the human vasculature system in terms of finding homing peptides for all tissue targets	intended not for just one condition but to create a molecular targeting map for the human vasculature system usable for future clinical applications	M13 phage CX7C library	53
study completed, October 2015 (should be noted that there are a large number of clinical trials using this virus derived peptide; this is just one example)	Study of AMG-386 in Combination With Paclitaxel and Carboplatin in Subjects with Ovarian Cancer	Trebananib (AMG-386) is a peptibody discovered through phage display that blocks the interaction between angiopoietin-1 and angiopoietin-2; blocking this interaction reduces angiogenesis and therefore the growth of tumors; evaluated was a combined treatment using AMG-386 with paclitaxel and carboplatin as a treatment for stages II–IV of epithelial ovarian, primary peritoneal, and fallopian tube cancers	stages II–IV of epithelial ovarian, primary peritoneal, and fallopian tube cancers	three filamentous phage libraries were used called TN8-IX, TN12-I, and Linear (1.0×10^{10} independent transformants)	52, 54
study completed February, 2015	DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas	phage library derived sequence CDCRGDCFC (often called DNX-2401 or 24-RGD-4C) homes to multiple tumor types (including carcinoma, sarcoma, and melanoma); study was to determine the highest tolerable dosage and to determine the effect of the peptide on tumors	brain tumors	phage library	49, 52

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

Table 2

Pathogen-Targeting Peptides Derived from Virus Libraries

	pathogen	viral library/virus type	targeting peptide sequence	applications	ref
parasite	*Rhipicephalus (Boophilus) microplus* (cattle tick)	fUSE5/15-met//M13 phage	RNLWPGDLRWVGWH, RLGPLHFLNAWGHDH	potential targeted chemotherapy/ vaccination strategies	55
	Plasmodium (the causative agent of malaria)	XCX₈CX//M13 phage	PCQRAIFQSICN	inhibited *Plasmodium* invasion of salivary gland and midgut epithelia to prevent malaria	56
	Schistosoma japonicum schistosomula	Ph.D.-12//M13 phage	YSGLQDSSLRLR	exhibited potent schistosomicidal activity in vitro; also a possible drug carrier	57
	Leishmania major	hexapeptide library//M13 phage	MAAKYN	inhibits *L. major* growth kinetics in vitro and reduces cutaneous lesions	51
yeast/fungus	*Candida albicans*	Ph.D.-12//M13 phage	ELMAVPVPLPPA, SEYTSQLIFTAT, SEFSYIVIDTSL, ELTAILVSPAPL, ELNAQHIMEPKY, ELIPMLIMQSTS, EDYSTIMKTLAH, STPKSPHSVASH, AVQHNPTHPFYP	rapid, highly specific diagnosis of *Candida albicans* infection	58
	Candida albicans disease biomarker (antisecreted aspartyl proteinase 2 IgG antibody)	antibody M13 phage-display library//M13 phage	VKYTS	highly sensitive diagnosis and detection of *Candida albicans* infection (indirectly by looking for the immune response)	59, 60
	Paracoccidioides brasiliensis	CX7C//M13 phage	CGSYGFNAC	selectively kills only virulent *Paracoccidioides brasiliensis* yeasts to treat Paracoccidioidomycosis	61
virus	*Avian influenza A H5N1*	VHH library//M13 phage	AAGPLSWYAHEFLEYSGHEYNY, TEHRGFDDNDYVLPALGARAANY, AAPLPDCYSGSWSPFTDEYNY	diagnosis of H5N1 infection	62
	Avian influenza A H7N2	VHH library//M13 phage	see ref for full-length sequences	diagnosis of H7N2 infection	63
	orthopoxviruses	Ph.D.-12//M13 phage	TADKLLYGLFKS	orthopoxvirus detection	64
bacteria	*Klebsiella pneumoniae*	naïve human single chain fragment variable//M13 phage	see ref; sequences not provided.	*Klebsiella pneumoniae* antibody therapeutics and vaccines	65
	Listeria monocytogenes	VHH library//M13 phage	AARRGPGTSVLSDDYDY, ATTRTPRVRLPTESREYTY	detection and diagnosis of the foodborne pathogen *Listeria monocytogenes*	66
	Salmonella	Ph.D.-12//M13 phage	NRPDSAQFWLHH	rapid *Salmonella* testing	67
	E. coli and *P. aeruginosa*	Ph.D.-12//M13 phage	RLLFRKIRRLKR	bactericidal activity against *E. coli* and *P. aeruginosa*	68
	Staphylococcus aureus	Ph.D.-12//M13 phage	VPHNPGLISLQG	detection and diagnosis of *Staphylococcus aureus* infection	68
	Mycobacterium leprae	Ph.D.-12//M13 phage	LEQCQES, LEQCQES	diagnosis and potential vaccine for leprocy	69
	Mycobacterium tuberculosis	Ph.D.-7//M13 phage	WHLPLSL	diagnosis of tuberculosis	70

Table 3

Summary of Human Cell-Targeting Peptides Derived from Virus Libraries

	organism/cell type	viral library	targeting peptide sequence	applications	ref
cancer cells	human breast carcinoma SKBR-3	f8/8 landscape//M13 phage	VSSTQDFP	SKBR-3 breast cancer cells internalization	71
	basal cell adhesion molecule (BCAM) and laminin subunit alpha 5 (LAMA5) of human colorectal cancer cells	Ph.D.-7//M13 phage	ASGLLSLTSTLY, SSSLTLKVTSALSRDG	impairs adhesion of KRAS mutant colorectal cancer cells to endothelial cells	72
	esophageal cancer cells	Ph.D.-12//M13 phage	RALAHPRDHPDL, ATCSMLLSRNEA	early screening of esophageal cancer	73
	PPC-1 human prostate carcinoma cell	T7 library//T7 phage library	(R/K)XX(R/K)	PPC-1 human prostate carcinoma cell targeting	74
	PC3 human prostate cancer cells in vitro and in vivo	Ph.D.-12//M13 phage	KQFSALPFNFYT	targeted delivery of doxorubicin to prostate cancer cells	75
	colon cancer cell line SW480	Ph.D.-7//M13 phage	VHLGYAT	imaging	76
	U87MG malignant glial cell line	Ph.D.-12//M13 phage	VTWTPQAWFQWV	drug delivery	77
	hepatocellular carcinoma cell line BEL-7402	Ph.D.-12//M13 phage	AGKGTPSLETTP	drug delivery	78
	cervical carcinoma	CX9C//M13 phage	C(R/Q)L/RT(G/N)XXG(A/V)GC	drug delivery	79
	human colorectal cell line WiDr	Ph.D.-12//M13 phage	HEWSYLAPYPWF	gene delivery	80, 81
	neuroblastoma and breast cancer cell	Ph.D.-12//M13 phage	VPWMEPAYQRFL	imaging	82, 83
	acute myeloid leukemia cells	X_7 AAV2//adeno-associated virus 2	NQVGSWS	acute myeloid leukemia gene therapy	84
	HO-8910 ovarian cancer cells	Ph.D.-7//M13 phage	NPMIRRQ	potential ovarian cancer diagnosis tool	85
	human gastric adenocarcinoma cancer cells	Ph.D.-12//M13 phage	ETAPLSTMLSPY	peptide can bind to the surface of gastric adenocarcinoma cancer cells and reverse their multidrug resistance	86
			IHKDKNAPSLVP	high affinity and specificity binding to gastric adenocarcinoma cancer cells	87
	HO-8910 ovarian cancer cells; promiscuous ligand targeting of lung and pancreatic cancer cells	Ph.D.-C7C//M13 phage	SWQIGGN	control of ovarian cancer cell migration, viability, invasion, and adhesion capacity	88
		F8/9//M13 phage	GSLEEVSTL, GEFDELMTM	promiscuous ligand targeting of lung and pancreatic cancer cells for targeted doxorubicin delivery	89
stem cells	primate embryonic stem cells	Ph.D.-12//M13 phage	APWHLSSQYSRT	imaging	90
	human mesenchymal stem cells	Ph.D.-7//M13 phage	EPLQLKM	recruitment of hMSCs	91
	human pluripotent stem cell-derived progenitor cell lines	Ph.D.-12//M13 phage	EWLFEFPTPVDA, DWIATWPDAVRS	cell isolation	92

organism/cell type	viral library	targeting peptide sequence	applications	ref
adult neural stem cell surface receptors (one or more)	Ph.D.-7//M13 phage	KLPGWSG	enhanced neural stem cell neuronal differentiation in vitro	93
human embryonic progenitor cell line W10	Ph.D.-12//M13 phage	DWLWSFAPNVDT	imaging	94

Table 4

Summary of Tissue-Targeting Peptides Derived from Virus Libraries in Preclinical or Clinical Trials

	tissue type	viral library	targeting peptide sequence	applications	ref
tumor	MDA-MB-435 breast carcinoma xenografts	CX$_7$C//T7 phage	CGNKRTRGC	MDA-MB-435 breast carcinoma xenografts targeting	95
tissues	p32-expressing breast tumors	CX7C//T7 phage	CKRGARSTC	drug delivery to p32-expressing breast tumors	96
	gastric tumor tissues	Ph.D.-12//M13 phage	AADNAKTKSFPV	imaging	97
	bladder tumor tissues	CX$_7$C T7//T7 phage	CSNRDARRC	imaging	98
		Ph.D.-C7C//M13 phage	CSSPIGRHC	imaging	18
	vasculature of human gastric cancer	Ph.D.-C7C//M13 phage	CGNSNPKSC	imaging	99
	human lung adenocarcinoma	CX$_7$C//M13 phage	CAKATCPAC	imaging	100
		CX$_7$C//M13 phage	LYANSPF	imaging	101
other tissues	brown adipose tissue	mixture of cyclic CX$_7$C and CX$_8$C//M13 phage	CPATAERPC	imaging	102
	normal breast tissue	CX$_7$C//T7 phage	CPGPEGAGC	breast tissue targeting	103
	ischemic stroke tissue	CX$_7$C//phage T7	CLEVSRKNC	imaging	104
	endothelium of the pulmonary vasculature	X$_7$AAV2//adeno-associated virus 2	ESGHGYF	gene delivery	105
	tympanic membrane transport to middle ear tissue	Ph.D-12//M13 phage	SADSTKTTHLTL	targeted transportation across the tympanic membrane to the middle ear for patients infected with otitis media	106
	brain microvasculature endothelial cell tissue	heptapeptide AAV2//adeno-associated virus 2	NRGTEWD	targeted gene-therapy vector able to ameliorate severe cerebrovascular pathology of incontinentia pigmenti	107
	central nervous system and other tissues including brain, spinal cord, muscle, pancreas, and lung tissues	AAV capsid library//adeno-associated virus 1	VDFAVNTEGVYSEPRPIGTRYLTRNL	targeted gene therapy for the central nervous system and other tissues including brain, spinal cord, muscle, pancreas, and lung tissues	108
	human bone marrow	CX7C//M13 phage	GGG, GFS, LWS, ARL, FGG, GVL, SGT	peptide motifs were isolated from a human patient in vivo to map potential targets of the vasculature system	53
	human fat tissue		EGG, LLV, LSP, EGR, FGV		
	human prostate tissue		AGG, EGR, GER, GVL		
	human skin		GRR, GGH, GTV, ARL, FGG, FGV, SGT		